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A ZUSAMMENFASSUNG 
 
Ziel der Doktorarbeit war die Analyse der Beteiligung der intrazellulären Domänen an der 
Regulation des humanen B2 Bradykinin Rezeptors im Hinblick auf Signaltransduktion, Rezeptor-
Desensibilisierung, und Rezeptor-Internalisierung. 
 
Im ersten Teil wurde der Einfluss von Rezeptordichte und Zelltyp sowohl auf Internalisierung 
wie auch Signaltransduktion des B2 Rezeptors untersucht. Es wurden die Eigenschaften des B2 
Rezeptors, stabil mit unterschiedlichem Expressionslevel exprimiert unter der Kontrolle zweier 
verschieden starker Promotoren in HEK 293 Zellen und endogenem B2 Rezeptor in humanen 
Fibroblasten analysiert. Wir konnten zeigen, dass zwei B2 Rezeptor-Antagonisten, Icatibant und 
B9430, die sich von Bradkyinin (BK) durch die Insertion von artifiziellen Aminosäuren 
unterscheiden, unter bestimmten Bedingungen zu partiellen Agonisten werden; zu diesem 
partiellen Agonismus kam es nur in HEK 293 Zellen, die eine hohe B2 Rezeptor-Expression 
zeigten, wohingegen dies in niedriger (HEK 293) oder endogen (Fibroblasten) exprimierenden 
Zellen nicht zu beobachten war. Allerdings resultierte langzeitige B9430-Stimulation in niedrig 
exprimierenden HEK293, wie auch in Fibroblasten, in einer starken Reduktion der 
Oberflächenbindung des Rezeptors, vergleichbar mit dem Effekt des endogenen Agonisten BK. 
Weitere Studien zeigten, dass im Gegensatz zu BK, welches die Oberflächenbindung durch 
Einleitung von Rezeptor-Internalisierung reduzierte, B9430 die Bindung an der Zelloberfläche 
durch eine Erniedrigung der B2 Rezeptor-Affinität herabsetzte, ohne dessen Internalisierung zu 
bewirken, ein Mechanismus, der so bisher noch nicht beschrieben wurde. 
 
Im zweiten Teil wurde die Rolle der intrazellulären Schleifen des B2 Rezeptors genauer erforscht. 
G-Proteine, Rezeptor-Kinasen und Adapter-Proteine des Internalisierungs-Komplexes 
interagieren sehr wahrscheinlich mit cytosolischen Domänen des Rezeptors. Um die 
Rezeptorsequenzen, die an diesen Interaktionen beteiligt sind, genauer zu definieren, wurden 
systematisch alle drei intrazellulären Schleifen entweder als Punktmutationen oder in Gruppen 
von 3-5 Aminosäuren zu Alanin mutiert (insgesamt 14 Mutanten), wobei alle Konstrukte stabil 
und isogen in HEK 293 Zellen exprimiert wurden. Unsere Ergebnisse zeigen, dass 
Veränderungen in der intrazellulären Schleife 1 (ICL-1) die Oberflächenexpression des Rezeptors 
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stark beeinflussen, wohingegen Rezeptor-Signalvermittlung und Internalisierung unverändert 
bleiben. Für die Aufrechterhaltung der Rezeptorlevel ist die DRY-Sequenz am N-Terminus der 
intrazellulären Schleife 2 (ICL-2) und die TERR-Sequenz am C-Terminus der intrazellulären 
Schleife 3 (ICL-3) von noch größerer Bedeutung, denn Gruppen-Mutationen verhindern entweder 
komplett die Oberflächenexpression des Rezeptors (erstere) oder reduzieren diese sehr stark 
(letztere). Sowohl ICL-2 als auch ICL-3 sind an der Interaktion mit dem G-Protein Gq/11 beteiligt, 
jedoch auf unterschiedliche Art und Weise. Sequenzen in ICL-2 beeinflussen eher die Kopplung, 
wohingegen Regionen in ICL-3 bevorzugt bei der Aktivierung von Gq/11 eine Rolle spielen. 
 
Aufgrund der bisher erhaltenen Ergebnisse wurde die Rolle der Aminosäuren der DRY- und 
TERR-Sequenz näher untersucht. Für bovines Rhodopsin wurde gezeigt, dass das Arginin im 
DRY motif (R3.50 Nummerierung entsprechend Ballesteros und Weinstein) (Ballesteros et al., 
1998) und ein Glutamat am cytosolischen Ende der Transmembran 6 (Ballesteros/Weinstein 
Position 6.30), entsprechend dem Glutamat in der TERR-Sequenz des B2 Rezeptors, interhelikal 
interagieren, wobei sie Rhodopsin in seiner inaktiven Konformation halten. Diese Interaktion in 
bovinem Rhodopsin ist auch bekannt als “ionic lock” (“ionische Sperre”) und wird vermutlich als 
Folge von Rezeptor-Aktivierung unterbrochen. Da der B2 Rezeptor einer der ganz wenigen 
Peptidrezeptoren der G-Protein-gekoppelten Rezptoren ist, bei dem neben Arginin 3.50 auch 
Glutamat 6.30 konserviert ist, wurde im dritten Teil der Doktorarbeit die strukturelle und 
funktionelle Rolle dieser beiden Aminosäuren im B2 Rezeptor analysiert. Zusätzlich wurde die 
Hypothese überprüft, ob diese beiden Aminosäuren auch im B2 Rezeptor eine ionische Bindung 
bilden, die daran beteiligt ist, seinen inaktiven Zustand aufrecht zu erhalten. Dieses Ziel wurde 
durch die Generierung von zwei Punktmutationen des Rezeptors, R3.50A und E6.30A, und deren 
ausführliche biochemische und funktionelle Charakterisierung, verfolgt. 
Unsere Studie zeigt, dass R3.50 eine duale Rolle spielt: es ist (i) entscheidend für die produktive 
Interaktion mit G-Proteinen und (ii) ist wahrscheinlich Teil einer Interaktion, in der es die 
Transmembrandomänen  TM3 und TM6 durch eine Ionenbindung mit Glutamat 6.30 und über 
einer Wasserstoffbrücke mit Threonin 6.26 verknüpft, wodurch die inaktive Konformation des 
Rezeptors in Abwesenheit von Agonisten stabilisiert wird. Auf den zweiten Punkt deutet die 
Tatsache, dass – mit Ausnahme der G-Protein Aktivierung – beide Mutanten, R3.50A und 
E6.30A, ein beinahe identisches Muster konstitutiver und semi-aktiver Aktivität zeigen, wie man 
es erwarten würde, wenn beide Aminosäuren miteinander interagieren.  
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Glutamat 6.30 dürfte einen zusätzlichen Interaktionspartner haben, da seine Mutation quantitativ 
immer stärkere Effekte zeigte als die Mutation von Arginin 3.50. Da eine saure Aminosäure an 
Position 6.30 unter den Peptiderezeptoren der G-Protein-gekoppelten Rezptoren nicht konserviert 
ist und häufig durch ein positiv geladenes Arginin oder Lysin ersetzt ist, müssen in dieser 
Unterfamilie unterschiedliche Mechanismen zur Stabilisierung des inaktiven Zustands existieren.  
 
Die G-Protein-gekoppelten Rezptoren sind ideale therapeutische Angriffspunkte, da sie einerseits 
auf der Zelloberfläche lokalisiert relativ gut zugänglich sind, andererseits durch ihre selektive 
Bindung endogener Liganden und ihre zellspezifische Expression hochspezifisch wirken. 
Genauere Kenntnisse über Strukturen, Unterschiede und Gemeinsamkeiten in ihrer Regulation, 
zu denen auch die vorliegende Arbeit ihren Beitrag leistet, sollten es ermöglichen ihr 
therapeutisches Potential durch rationale, struktur-basierte Medikamentenentwicklung noch 
besser auszuschöpfen. 
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B INTRODUCTION 
B.1 The kallikrein-kinin system (KKS) 
B.1.1 Historic background 
In 1925 the German surgeon Emil-Karl Frey observed a strong reduction in blood pressure when 
he injected the urine of humans into dogs. Together with the biochemist Heinrich Kraut, he 
attributed this effect to a substance with potential biological effects (Frey & Kraut 1926; Frey, 
1926). This substance was later termed kallikrein (KLK) (Kraut et al., 1930). In 1937, the 
biochemist Eugen Werle found that KLK is a proteolytic enzyme, which liberates the biologically 
active polypeptide kallidin (KD) from a plasma protein termed kininogen (Werle et al., 1937). 
Werle also observed the degradation/inactivation of kinins, identified these inactivators as 
peptidases, and termed them “kininases” (Werle & Grund, 1939). 
In 1949, it was discovered that trypsin, when incubated with blood, releases an agent that 
contracts the guinea-pig ileum (Andrade & Rocha e Silva et al, 1949). Since the response of this 
tissue developed slowly, the authors called the agent “bradykinin” (brady = slow). Later, 
bradykinin (BK) was purified and identified as a nonapeptide (Andrade & Rocha e Silva et al, 
1956). The exact sequence of BK was published by Swiss chemists and the nonapeptide could 
thereafter be chemically synthesized (Boissonnas et al., 1960). 
 
B.1.2 Kinins 
Nowadays, the peptides that are referred to as kinins comprise BK and Kallidin (Lys-BK) and 
their carboxypeptidase cleavage products, des-Arg9-BK and des-Arg10-Kallidin. BK is a 
positively charged nonapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) that can be found in 
almost all secretions of the body, i.e. urine, saliva, and sweat, but also in feces and several 
tissues, such as the heart, vasculature, blood, kidneys, liver, skin, small intestine, colon, pancreas, 
salivary glands, reproductive organs, lungs, and adrenal glands (Campbell et al., 1993); (Hibino 
et al., 1994); (Madeddu et al., 2001); (Meneton et al., 2001); (Patel et al., 1999); (Schremmer-
Danninger et al., 1999). KD has been found in the heart, urine, and blood circulation (Campbell 
et al., 1999); (Duncan et al., 2000). 
BK is released from its precursor, the high molecular weight kininogen (HMWK), through the 
action of plasma kallikrein. Kallidin is released from high and low molecular weight kininogen 
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through tissue kallikrein. BK can also be derived from KD by several amino peptidases through 
cleavage of the amino-terminal lysine. Cleavage of the carboxy-terminal arginine of BK and KD 
by carboxypeptidases yields the truncated derivatives des-Arg9-BK and des-Arg10-Kallidin. 
BK is produced in the body in response to many kinds of injuries and under inflammatory 
conditions. It is one of the most potent elicitors of pain and participates in normal physiological 
regulation (Stewart, 2004).  
 
B.1.3 Kinin receptors 
The effects of the kinins are mediated by their binding to the bradykinin receptors, subtypes B1 
and B2. These receptors belong to family A of the superfamily of G protein-coupled receptors 
(GPCRs) and share 36% sequence identity. In Figure B-1 a schematic view of the human B2 
receptor (B2R) is shown with comparison to the B1 receptor (B1R). The region of the potential 
Helix VIII in the C-terminus before the palmitotylation site is highly conserved. On the other 
hand, the sequence after Helix VIII shows no conservation (Menke et al., 1994) and is much 
shorter for the B2 receptor (Hess et al., 1992).  
BK and KD are selective high affinity ligands of the B2 receptor, whereas des-Arg9-BK and des-
Arg10-Kallidin are selective ligands of the B1 receptor. The B2 receptor is generally present in a 
wide variety of tissues, in contrast to the B1 receptor, which is expressed de novo under certain 
pathological conditions like inflammation and sepsis. 
Genomic sequencing of the human chromosomal regions encoding the B1 and B2 receptors 
revealed that the genes are located in a tandem orientation with the B2 receptor gene being 
proximal to the B1 receptor gene, separated by an intergenic region of only 12 kb (Cayla et al., 
2002). The close proximity of the two genes strongly suggests that they evolved from a common 
ancestor by a gene duplication event. 
B1R is one of few receptors belonging to GPCR family A which does not get internalized (Austin 
et al., 1997). Upon ligand stimulation, it responds with translocation to caveolae but these remain 
essentially on the cell surface (Sabourin et al., 2002); (Lamb et al., 2002). No phosphorylation of 
B1R either under basal conditions or after stimulation has been detected (Blaukat and Muller-
Esterl, 1997); (Pizard et al., 1999). 
The full-length human B2R is composed of 391 amino acids with a calculated molecular weight 
of 41 kDA (AbdAlla et al., 1996). In most primary and cultured cells, B2R is modified by 
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complex glycosylation resulting in a broad 60-80 kDa band after electrophoretic separation 
(Blaukat et al., 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. B-1: Schematic view of the sequence of the human B2 receptor compared to the B1 receptor. 
Depicted are the seven transmembrane domains, the three extracellular and intracellular loops and the 
position of the potential Helix VIII in the cytosol. Dark blue or light blue highlighted circles indicate that the 
corresponding amino acid is identical or similar, respectively. The third methionine, which is the starting 
point of all expression constructs used in this work, is marked red. The primary palmitoylation point at Cys324 
is shown with a wide grey bar, the alternative position Cys329 with a thinner grey bar. The green line marks 
the shorter B1 C-terminus. The black symbols (P, G) indicate additional residues present in the B1 receptor. 
 
B.1.4 The signaling pathways of the kinin receptors 
The kinin receptors couple after ligand stimulation to Gαq/11 proteins leading to activation of 
phospholipase C-β (PLC-β) and subsequent generation of second messengers: inositol-1,4,5-
triphosphate (Ins 1,4,5-P3), diacylglycerol (DAG) and release of intracellular calcium. In the 
blood vessels this increase in intracellular calcium can activate the NO/cGMP pathway that 
primarily mediates the strong hypotensive effect. NO diffuses from the endothelium to the 
smooth muscle where it activates guanylate cyclase. Prostaglandin I2 (prostacyclin) is another 
secondary mediator frequently released by kinins from the endothelium. Prostacyclin stimulates 
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cyclic AMP production in the smooth muscle cells. DAG and calcium activate several isoforms 
of protein kinase C (PKC) that participate in a number of cellular signaling pathways, including 
those that control cell proliferation (Tippmer et al., 1994); (Nishizuka, 1992). 
Kinin receptors can also activate phospholipase A2 and D as well as sphingosine kinase resulting 
in increased cellular concentrations of lipidic second messengers: arachidonic acid (subsequently 
converted to prostaglandins), phosphatidic acid, and sphingosine 1-phosphatase (Burch and 
Axelrod, 1987); (Blaukat et al., 2000); (Blaukat et al., 2001). 
Bradykinin induced Gαi stimulation has also been observed in several cell types. This involves 
the activation of the ERK/MAPK cascade and mitogenic signaling in certain tumour cell lines 
(Liebmann, 2001). The B2 receptor gene knockout mouse exhibits elevated blood pressure, 
increased heart/body weight ratio and an exaggerated pressure response to angiotensin II infusion 
and chronic dietary salt loading (Madeddu et al., 1997). 
 
B.1.5 Regulation of kinin receptors 
The kinins have a very short half-life, <15 s in the plasma (Roberts and Gullick, 1990). The 
physiologically active concentrations are presumably only locally generated. Kininases can 
cleave the kinins into shorter peptides with other biological specificities or into inactive peptides. 
Kininase I is also known as ACE (angiotensin I converting enzyme). It is localized primarily to 
the pulmonary vasculature. It destroys almost all circulating BK on a single passage through the 
pulmonary circulation. ACE is a carboxypeptidase, which cleaves BK successively at the 7-8 and 
5-6 bonds. ACE not only degrades the kinins but also transforms inactive Angiotensin I into 
active Angiotensin II. This provides a connection between the KKS and the RAS (Renin 
Angiotensin System). Any circulating BK that escapes cleavage by ACE can be cleaved by 
circulating carboxypeptidase N (CPN), which removes the C-terminal Arg residue. The resulting 
[des-Arg9]-BK is inactive at B2 receptors but is the preferred agonist for B1 receptors. BK is also 
cleaved by neutral endopeptidases (NEP; neprilysin), which are membrane-bound in much of the 
vasculature. They cleave BK at the Phe5 residue. Finally, BK is also cleaved by aminopeptidases, 
which remove the N-terminal arginine residue. Any single cleavage of the peptide chain totally 
inactivates BK for action at the B2 receptors. Thus, the development of peptide antagonists based 
on BK would likely necessitate blockage of the activities of all these enzymes. This holds true for 
peptidic antagonists but it is not decisive in development of small compounds. 
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B.2 G proteins and G protein-coupled receptors (GPCRs) 
B.2.1 G proteins 
The binding of extracellular ligands to GPCRs modulates their ability to catalyze guanine 
nucleotide exchange on intracellular heterotrimeric G proteins. The G proteins were discovered 
through intensive research on adenylylcyclase, an enzyme that converts ATP (Adenosin-5´-
triphosphate) to cAMP (cyclic Adenosin-3´, 5´-monophosphate). That gave rise to the question 
how the signal is mediated from the receptor to the adenylylcyclase and through which 
mechanisms. Rodbell et al. showed that a hormone could activate the adenylylcyclase only when 
GTP is present (Rodbell et al., 1971). Because this protein could bind GTP, it was called GTP-
binding protein or short form: G protein. Sternweis et al. and Northup et al. could purify, isolate 
and characterize this stimulating G protein, termed Gs (Sternweis et al., 1981); (Northup et al., 
1980). The finding that treatment of the cells with pertussis toxin blocked the inhibition of the 
adenylylcyclase (Katada and Ui, 1979) gave rise to the characterization of the inhibitory Gi 
proteins (Bokoch et al., 1984); (Katada et al., 1984). 
In the meantime more G proteins have been discovered and it is now clear which important 
impact they have by transmitting the signals between the receptors on the cell surface and the 
intracellular effector proteins. For their experiments, which lead to the discovery of the G 
proteins, A.G. Gilman and M. Rodbell were awarded the Nobel price in Medicine 1994. 
 
B.2.2 Functionality 
G proteins are heterotrimeric, composed of α-, β- and γ-subunits. In the inactive state the α-
subunit is GDP-bound and displays a high affinity for the βγ-subunit.  Through agonistic binding 
to the receptor, GDP is exchanged to GTP. That gives rise to a conformational change which 
provides the dissociation of the active α-subunit from the βγ-subunit. The GTP bound Gα and the 
βγ-complex are then able to interact with different effector enzymes and ion-channels leading to 
the observed physiological response. Because of its intrinsic GTPase activity, the Gα-subunit 
hydrolyzes bound GTP to GDP; the GDP-bound α-subunit then re-associates with the βγ-subunit 
returning all subunits to the inactive state. 
 The α-subunit has a molecular weight of 39-52 kDa, the β-subunit 35-36 kDa and the γ-subunit 
∼7-10 kDa. The α-subunit is divided into four groups according their DNA-sequence homology: 
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Gs, Gi, Gq and G12. Gq stimulates the β-isoform the Phospholipase C (Taylor et al., 1991); (Lee et 
al., 1992). 
 
B.2.3 Superfamily of GPCRs 
GPCRs, or seven transmembrane receptors, constitute of one of the largest superfamilies in the 
human genome (Lagerstrom and Schioth, 2008). All GPCRs display a similar structure. They are 
composed of a single polypeptide chain of variable length that spans the lipid bilayer seven times, 
forming transmembrane helices and alternating extracellular and intracellular loops.  
Based on sequence similarity, the GPCRs are divided into three subfamilies: Family A: 
rhodopsin/β-adrenergic-receptor-like, family B: glucagon-receptor-like and family C: 
metabotropic glutamate neurotransmitter receptor-like. 
Family A is by far the largest family with more than 300 identified receptors (Fig. B-2). The 
members of this family do not share a high overall sequence identity but they do have a few 
highly conserved residues and motifs (ca. 20 amino acids in all) in analogous positions, mostly 
located in the transmembrane regions. The E/DRY sequence at the cytosolic end of 
transmembrane domain III (TMD III) is one of the most conserved motifs. Another highly 
conserved sequence is the NPxxY sequence (where x usually represents a hydrophobic residue 
and N is occasionally substituted for D) located at the C-terminus of TMD VII. High 
conservation of protein sequences often indicates important functional and structural roles. 
 
Fig. B-2: Family A: rhodopsin/β-adrenergic-receptor-like. Family A receptors are characterized by a series of 
highly conserved residues (black letter in white circles). A majority of the receptors have a palmitoylated cysteine in 
the carboxy-terminal tail causing formation of a putative fourth intracellular loop (Figure taken from U. Gether, 
Endocrine Reviews, Vol: 21: 90-113, 2000). 
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Family B (glucagon-receptor-like GPCRs) includes approximately 20 different receptors of a 
variety of peptide hormones and neuropeptides, such as vasoactive intestinal peptide (VIP), 
calcitonin and glucagon. Characteristic of family B receptors is a large extracellular amino 
terminus containing several cysteines, forming a network of disulfide bridges. (Fig. B-3, left). 
Family C receptors include among others the metabotropic glutamate and γ-aminobutytic acid 
(GABA) receptors, calcium receptors and putative taste receptors (Fig. B-3, right). 
                            
Fig. B-3: Family B: glucagon-receptor-like and family C: metabotropic glutamate neurotransmitter receptor-
like GPCRs. Family B receptors (left) are characterized by a long amino terminus containing several cysteines 
presumably forming a network of disulfide bridges. Family C receptors (right) are characterized by a very long 
amino terminus (∼600 amino acids). Another characteristic of the C receptors is a very short and highly conserved 
third intracellular loop (Figure taken from U. Gether, Endocrine Reviews, Vol: 21: 90-113, 2000). 
 
 
B.2.4 The highly conserved DRY motif 
The E/DRY or DRY motif is located at the boundary between TMD III and intracellular loop 2 of 
class A GPCRs (rhodopsin family). It is one of the most intensively researched conserved motifs 
and is named for the single letter designation of its constituent amino acids, Asp-Arg-Tyr. 
Intensive work has been focused on understanding the mechanisms of receptor activation and 
interaction with G proteins, and both the acidic (Asp) and basic (Arg) residues are known to be 
important for isomerization of receptors between inactive and activated conformations (Flanagan, 
2005). 
 One part of this thesis focused on the role of the highly conserved arginine positioned at R3.50 
(numbering according to the numbering scheme of Ballesteros and Weinstein) (Ballesteros et al., 
1998) in the DRY motif. The numbering scheme from Ballesteros and Weinstein is used here and 
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later in this study. According to the numbering scheme, the most conserved residue in a 
transmembrane segment is named by the number of the helix followed by the number 50. 
Upstream residues are then named by counting down, downstream residues by counting up from 
50. From the structure of some prototypical receptors belonging to family A GPCRs it is known 
that this basic arginine R3.50 forms stabilizing interactions with the neighboring aspartic acid or 
glutamic acid (E3.49) and/or with another charged residue (E6.30) on helix 6 (Ballesteros et al., 
2001); (Angelova et al., 2002); (Greasley et al., 2002); (Shapiro et al., 2002); (Zhang et al., 
2005), thereby constraining GPCRs in the inactive conformation. The crystal structure of the 
ground state of rhodopsin indicates that the highly conserved arginine is engaged in a double salt 
bridge with the adjacent glutamic acid (E3.49) and with the glutamic acid (E6.30) on helix 6 
(Palczewski et al., 2000); (Teller et al., 2001), suggesting that disruption of these salt bridges may 
be a key step in receptor activation (Cohen et al., 1993); (Greasley et al., 2001); (Angelova et al., 
2002). These stabilizing interactions in bovine rhodopsin keeping the receptor in its inactivated 
state are also known as the “ionic lock”. Mutation of the glutamic acid/aspartic acid of the 
E/DRY motif has been proposed to induce a conformational change that repositions the arginine 
from its polar pocket, resulting in the ability of some GPCRs to adopt an active conformation 
(Scheer et al., 1996); (Scheer et al., 1997); (Cotecchia et al., 2002). For the human bradykinin B2 
receptor it is, to our knowledge, not known if the highly conserved arginine R3.50 forms 
stabilizing interactions with the neighboring aspartic acid (D3.49) and/or with another charged 
residue (E6.30) on helix 6 or other additional residues. Therefore we set out to investigate this 
question with a focus on residues R3.50 and E6.30  (Results section E.3). 
 
B.2.5 Crystal structures of GPCRs 
The first crystal structure of a GPCR was that of inactive bovine rhodopsin (Palczewski et al., 
2000). In 2007 the structure of the human β2-adrenergic receptor (β2AR) was solved (Rasmussen 
et al., 2007). It was crystallized in a complex with an antibody fragment (β2AR-Fab). This was 
followed by the higher resolution structure of an engineered β2AR with T4 lysozyme replacing 
the third cytoplasmic loop (β2AR-T4) (Cherezov et al., 2007). These structures contain the 
inverse antagonist carazolol. They define the overall architecture of β2AR and the structure of the 
ligand-binding pocket. In 2008 the crystal structure of the turkey β1-adrenergic receptor was 
reported (Warne et al., 2008). This 2.7 Å resolution crystal structure is in complex with the 
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inverse antagonist cyanopindolol. The modified receptor was thermostably improved by earlier 
extensive mutagenesis. The ligand-binding pocket contains 15 side chains from amino acids 
residues in four transmembrane α-helices and extracellular loop 2. In the crystal structure of the 
β2AR (Rasmussen et al., 2007) it is argued that the “ionic lock” (described in B.2.4) is not present 
in the inactive conformation because the distance (6.2 Å) between R131 (R3.50) and E268 
(E6.30) is too long for formation of a hydrogen bond. This suggests that at least for this receptor, 
the ionic look is not an essential feature of the inactive state. In Fig. B-4 a comparison of the 
β2AR and rhodopsin structures is shown (Rasmussen et al., 2007).  
 
Fig. B-4: Comparison of β2AR and rhodopsin structures (Rasmussen 2007): β2AR is compared with structures 
of inactive and light-activated rhodopsin around the conserved E/DRY sequence in TM3. The dashed line shows the 
distance between the arginine in TM3 and glutamate in TM6. 
 
The crystal structure of the ligand-free GPCR opsin was recently reported (Park et al., 2008). In 
2008 the first crystal structure of a GPCR in its activated state was reported (Scheerer et al., 
2008). In this structure, a synthetic peptide derived from the main receptor binding site of the 
heterotrimeric G protein, the carboxy terminus of the α-subunit (GαCT)-stabilizes Opsin. 
Compared with the inactive receptor structures, the hallmarks of the activated Ops*-GαCT 
complex structure are an outward tilt of transmembrane helix 6 and a smaller motion of 
transmembrane helix 7 at the inner surface of the cell membrane. These movements open a cleft 
that presents the ligand-binding site to the G protein. Further, the “ionic lock” is broken and 
arginine R3.50 is released from E3.49 and E6.30. In Scheerer and colleagues’ opsin complex the 
activating ligand, all-trans retinal, is not present. It is well known that active conformations of 
unliganded receptors, including opsin, exist in equilibrium with the inactive state (Scheerer et al., 
2008).  
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B.3 Receptor antagonists 
A receptor antagonist is a type of receptor ligand or drug that does not provoke a biological 
response by itself upon binding to a receptor, but blocks or dampens agonist-mediated responses. 
In pharmacology, antagonists have affinity but no efficacy for their cognate receptors, and their 
binding will disrupt the interaction and inhibit the function of an agonist or inverse agonist at the 
receptor. The effects of antagonists are mediated by binding either to the active site or allosteric 
sites on receptors. They may also interact at unique binding sites that are not normally involved 
in the biological regulation of the receptor’s activity. The longevity of the antagonist-receptor 
complex determines whether the antagonistic activity is reversible or irreversible. The majority of 
antagonists achieve their potency by competing with endogenous ligands or substrates at 
structurally defined binding sites on receptors (Hopkins and Groom, 2002). Antagonists of 
GPCRs are widely used drugs. Two classical examples are angiotensin receptor blockers (ARBs) 
and β-adrenergic blockers (β blockers), which block the angiotensin II type 1 receptors and β-
ARs, respectively.  
A milestone in BK antagonist research was the discovery of icatibant, also known as HOE-140 or 
Je049. This was achieved in Germany in 1991 by investigators at Hoechst. They introduced a 
tetrahydroisoquinoline-3-carboxylic acid (Tic) and an octahydroindole-2-carboxylic acid (Oic); 
the latter change blocked the action of carboxypeptidase N (CPN). HOE-140 was the first BK 
antagonist with high potency and duration of action in vivo (Lembeck et al., 1991). The drug 
Firazyr (icatibant) was launched in 2008 in all EU countries for the treatment of hereditary 
angioedema (HAE) through inhibition of the B2R. There are, however, also some reports that 
icatibant might not always act entirely as an antagonist. (Houle et al., 2000) found that a GFP 
(green fluorescent protein)-fusion protein of the rabbit B2R (80% sequence identity with human 
B2R) responded to prolonged incubation with icatibant with slow translocation into the cells. 
Liebmann showed that in some tumor cell lines icatibant acted as a mitogenic agonist, stimulating 
cell growth and ERK1/2 phosphorylation (Liebmann, 2001). The latter was also reported for 
HEK 293 cells expressing recombinant B2R (Morissette et al., 2007).  
The next major improvement in the development of BK antagonists came from the Stewart 
laboratory with the introduction of α-(2-indanyl)-glycine (Igl) (Gera and Stewart, 1996); (Stewart 
et al., 1996). This introduction was done in for example B9430 with a D-Igl at position 7 and L-
Igl at position 5. This gave an extremely potent and long-acting antagonist highly resistant to 
kininases. B9430 exhibits high potency at B2 receptors but it is also a quite potent antagonist for 
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B1 receptors (Stewart et al., 1996). This property suggests that it may also have promise as an 
agent for treatment of chronic, as well as acute, inflammation.  
Non-peptide bradykinin B2 antagonists that are potent, specific and orally available have been 
reported by investigators at Fujisawa (Griesbacher and Legat, 1997), Sanofi (Pruneau et al., 
1999) and Novartis (Dziadulewicz et al., 2000). Until now there are no reports of clinical trials of 
non-peptide BK antagonists. The Stewart laboratory reports that non-peptide BK antagonists 
have been developed as anti-cancer agents (Stewart, 2004). Potent antagonists such as B9430 did 
not inhibit cancer cell growth in vitro or in vivo. But when B9430 was cross-linked at the amino 
end with a suberimidyl linker, the dimeric product, B-9870, was a potent anti-cancer compound, 
both in vitro and in vivo in nude mouse xenografts (Chan et al., 1996). B-9870 (also known as 
CU-201) is active against a wide range of cancers, and is under development at the US National 
Cancer Institute as a possible treatment for lung cancer (Chan et al., 2002).    
           
B.4 Functional selectivity 
In the past the definition of whether a ligand of a G protein-coupled receptor (GPCR) was 
considered an agonist, partial agonist or antagonist depended only on the resulting activation of 
the cognate G protein α-subunit(s) through the receptor after binding. An activated GPCR was 
generally assumed to be turned off by phosphorylation via GRKs (G protein-coupled receptor 
kinases), followed by recruitment of arrestins to the phosphorylated residues, which consequently 
resulted in sequestration of the receptor to intracellular compartments via clathrin-coated pits or 
caveolae. In recent years, however, it has become clear that stimulation of a GPCR may also 
result in G protein-independent activation of other signaling pathways. It is now widely accepted 
that different ligands can induce different receptor conformations which may result in differential 
activation of the various pathways (Perez and Karnik, 2005); (Vauquelin and Van Liefde, 2005); 
(Urban et al., 2007). Some terms for this phenomenon include functional selectivity, agonist-
directed trafficking, and biased agonism. Recently, it has been suggested that the number of 
different terms should be limited by using the term “functional selectivity” or as a viable 
alternative, “ligand-induced differential signaling” (Urban et al., 2007). In the extreme case a 
functional selective ligand can act as both an agonist and an antagonist at one receptor. Better 
knowledge of the potential functionally selective conformations of receptors could be of great 
help when dealing with drug discovery. Drugs could then be developed that affect specific 
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conformations of a given GPCR that could then couple to specific signaling pathways that may, 
ultimately, lead to reduced side effects. 
In the present study much work was done with icatibant and B9430 mostly known as antagonists 
for the B2R. As seen later, both peptides seem to have the properties of being functional selective 
ligands upon coupling and activation of the wild type B2 receptor. 
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C AIMS OF THE THESIS 
A future rational, structure-based and therefore less expensive development of agonists and 
antagonists would greatly benefit from a better understanding of the regulation and signal 
transduction mechanisms of the G-protein-coupled receptors (GPCRs). Deeper insights into the 
similarities and, in particular, the differences in this regard between GPCR subfamilies and 
receptor subtypes should result in more specific drugs with fewer side effects. 
 
The principal goal of this thesis was to investigate the role of the intracellular domains in the 
signal transduction and regulation of the human bradykinin B2 receptor. B2R belongs to the 
subfamily of the peptide receptors in the family of the rhodopsin/β-adrenergic-like GPCRs. 
 
For the this purpose we applied the following working program: 
• Pharmacological and biochemical characterization of the endogenously and 
recombinantly expressed wild type human bradykinin B2 receptor, including receptor 
binding properties, internalization, and functional selectivity of various B2 agonists and 
antagonists. 
• Mutagenesis studies (either as point mutants or in groups of 3-5 amino acids to alanines) 
on the intracellular receptor domains to identify sequences participating in interactions 
with G proteins, receptor kinases and arrestins.  
• Determination of the presence of the “ionic lock” and the role of the participating amino 
acids in the inactive human bradykinin B2 receptor. 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 17
D MATERIAL AND METHODS 
D.1 Material 
D.1.1 Equipment 
Balances:  
Analytic Balance, A 120 S (0-12 g range) Sartorius, Göttingen 
Analytic Balance, 3716MP (0-250 g range) Sartorius, Göttingen 
β-Counter:  
Liquid Scintillation Analyzer, Mod. 2300TR Packard, Meriden, CT 
β-γ-Counter, LB122 Berthold Technology, Canada 
Cell Incubators:  
Type B5060 EC-CO2 Heraeus Sepatech, München 
Centrifuges:  
Kontron, Centrikon H-401 with rotor A8.24 Kontron Instruments, Eching 
Heraeus, Varifuge 3.2 RS Heraeus Sepatech, München 
Heraeus, Sepatech Biofuge A (rotor 1230) Heraeus Sepatech, München 
Heraeus, Sepatech Biofuge A (rotor 3042) Heraeus Sepatech, München 
Clean Bench:  
BDK 7419, Mod. UVF 6.18S BDK, Sonnenbühl-Genkingen 
Herasafe type HS18/2 Heraeus Instruments, München 
ELISA-Reader:  
DigiScan 400 ASYS Hitech GmbH, Austria 
PCR Thermal Cycler:  
Primus type 25 MWG-Biotech, Ebersberg 
Power supply:  
Type EPS 301 Amersham-Pharmacia-Biotech 
Mod. 2103 LKB, Biochrom 
Protein Transfer Appartus:  
XCell SureLockTM Mini-cell 
Snap i.d. protein detection system  
Invitrogen, Karlsruhe 
Millipore, Schwalbach, Germany 
Sonifier:  
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Type B12 Branson Sonic Power Company, Danburg 
Spectral Confocal Microscope:  
Zeiss LSM 410 Carl Zeiss, Thornwood, NY, USA 
Fluorescence Microscope:  
Olympus IX-70 Olympus Optical Co., LTD, Tokyo, Japan 
Other Equipments:  
2D-Electrophoresis apparatus, HTLE-7000-02 CBS, Del Mare, USA 
Dounce homogenizer, type 853202 B.Braun, Melsungen, Germany 
 
D.1.2 Chemicals and materials  
Chemicals for the molecular biology techniques 
Gel extraction Kit Qiagen (Hilden, Germany) 
QIAprep Spin Miniprep (and Maxiprep) Kit Qiagen (Hilden, Germany) 
PCR primers Invitrogen (Groningen, Netherlands) 
 
Enzymes 
Restrictase Bam HI            New England BioLabs (England) 
Restrictase Hind III            Hybaid (Heidelberg, Germany) 
Restrictase Xho I                       New England BioLabs (England) 
T4-DNA ligase            Roche (Mannheim, Germany) 
Taq DNA polymerase           Qiagen (Hilden, Germany) 
Pfu DNA polymerase            Strategene (La Jolla, CA, USA) 
 
Cell culture  
DMEM –medium PAA (Cölbe, Germany) 
DMEM phosphate-free-medium PAA (Cölbe, Germany) 
Dulbecco´s PBS (1×) PAA (Cölbe, Germany) 
Trypsine/EDTA (1×)  PAA (Cölbe, Germany) 
Poly-D-lysine hydrobromide  Sigma (Taufkirchen, Germany)  
FuGENE 6 Roche (Mannheim, Germany) 
FCS  PAA (Cölbe, Germany) 
MATERIAL AND METHODS 19
Hygromycin B PAA (Cölbe, Germany) 
     
Enzyme inhibitors 
Aprotinin Sigma (Taufkirchen, Germany) 
Bacitracin Sigma (Taufkirchen, Germany) 
Captopril Sigma (Taufkirchen, Germany) 
Leupeptin Sigma (Taufkirchen, Germany) 
1.10-Phenantroline MERCK (Darmstadt, Germany) 
Pefabloc SC MERCK (Darmstadt, Germany) 
Pepstatin A Sigma (Taufkirchen, Germany) 
Sodium orthovanadate Sigma (Taufkirchen, Germany) 
 
Detergents  
CHAPS Sigma (Taufkirchen, Germany) 
Nonident P-40 Sigma (Taufkirchen, Germany) 
SDS Serva (Heidelberg, Germany) 
Triton X-100 Sigma (Taufkirchen, Germany) 
Tween 20 Sigma (Taufkirchen, Germany) 
 
Antibodies 
Anti-HA-antibody, rat monoclonal clone 3F10 Roche (Mannheim, Germany) 
Anti-HA matrix, immobilized, rat monoclonal Roche (Mannheim, Germany) 
Anti-HA Affinity Gel beads Sigma (Taufkirchen, Germany) 
Red Anti-HA Affinity Gel beads Sigma (Taufkirchen, Germany) 
Phospho-p44/42 MAPK mouse monoclonal Cell Signaling (Beverley, MA) 
P42 MAP Kinase mouse monoclonal Cell Signaling (Beverley, MA) 
Anti-β-arrestin mouse monoclonal BD Transduction labs (Franklin Lakes, NJ) 
HRP-labeled-anti-HA antibody, rat monocl. Roche (Mannheim, Germany) 
HRP-labeled goat anti-rabbit antibody DAKO (Glostrup, Denmark) 
HRP-labeled rabbit anti-rat antibody  DAKO (Glostrup, Denmark) 
HRP-labeled horse anti-mouse antibody New England BioLabs, England 
 
MATERIAL AND METHODS 20
Radioactive chemicals 
Myo-[2-3H]-inositol (21Ci/mmol) Perkin-Elmer Life Sciences (Boston, MA) 
[2,3-Prolyl-3,4-3H]bradykinin (108 Ci/mmol) Perkin-Elmer Life Sciences (Boston, MA) 
[3H]NPC17731             Perkin-Elmer Life Sciences (Boston, MA) 
 
Protein biochemistry 
NuPAGE Novex 4-12 % Bis Tris Gel Invitrogen (Karlsruhe, Germany) 
NuPAGE LDS sample buffer Invitrogen (Karlsruhe, Germany) 
Nitrocellulose membrane 0.45 µm BioRad (Munich, Germany) 
Whatman Filterpaper Nr.1 Whatman, Ammerbuch, Germany 
HyperFilm ECL Amersham (Buckinghamshire, UK) 
Chemiluminescence’s reagents plus Perkin-Elmer Life Sciences (Boston, MA) 
 
Miscellaneous 
AG 1-X8 anion exchange columns  BioRad (Munich, Germany) 
Sulfo-NHS-SS-Biotin 
Bradykinin 
Pierce (Rockford, IL) 
Bachem (Heidelberg, Germany) 
Icatibant 
Liquid scintillation mixture 
Jerini AG (Berlin, Germany) 
ZINSSER ANALYTIC (Frankfurt, Germany) 
Micro BSA protein assay reagent Pierce (Rockford, IL) 
  
  
  
• B9430 was a generous gift from Dr. John M. Stewart (University of Colorado Health Sciences 
Center, Denver, CO) 
 
• All other reagents were of analytical grade and are commercially available from MERCK, 
SIGMA and ROTH. 
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D.1.3 Strains and cell lines 
E. coli Top 10 (Invitrogen) 
Lab. Strain # 1557 
Genotype: F   mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lac X74 deoR A1 araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG   
 
Flp-InTMT-RexTM-293 (Invitrogen) 
Cell type:  Human Embryonic Kidney (HEK) cells 
Cytogenetics:  2n=46 
This cell line contains a single stably integrated FRT site at a transcriptionally active genomic 
locus. 
 
Human foreskin fibroblasts (HF-15) 
Provided generously from Prof. Roscher (Forschungszentrum der Univ. Kinderklinik der LMU, 
Munich, Germany) 
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D.1.4 Expression vectors 
 
pcDNA5/FRT vector 
Comments for pcDNA/FRT        
CMV promoter: bases 232-819                                                                            
                                                                         CMV 
forward priming site: bases 769-78 
T7 promoter/priming site: bases 863-882                                                        
Multiple cloning site: bases 895-1010 
BGH reverse priming site: bases 1022-1039 
BGH polyadenylation signal: bases 1028-1252 
FRT site: bases 1536-1583 
Hygromycin resistance gene (no ATG): bases 1591-2611                      
SV40 early polyadenylation signal: bases 2743-2873                                              
pUC origin: bases 3256-3929 (complementary strand) 
bla promoter: bases 4935-5033 (complementary strand) 
Ampicilin (bla) resistance gene: bases 4074-4934 (complementary strand)  
                                                                                                          
Fig. D-1: Schematic representation of the pcDNA5/FRT (Invitrogen). 
The vector was designed for stable expression of the gene of interest in mammalian hosts. It has a multiple 
cloning site that contains cleavage sites for several common restriction endonucleases. 
 
pOG44 vector 
Comments for pOG44 vector: 
CMV promoter: bases 234-821 
Synthetic intron: bases 871-1175 
FLP gene: bases 1202-2473 
SV40 early polyadenylation signal: bases 2597-2732 
pUC origin: bases 3327-3993 
Ampicilin resistance gene: bases 4138-4998 
 
 
                                                                                                  
Fig. D-2: Schematic representation of the vector pOG44 (Invitrogen). 
This vector expresses the Flp recombinase under the control of the CMV promoter. Flp recombinase is a 
member of the integrase family of recombinases, which mediates a site-specific recombination reaction 
between interacting DNA molecules via pairing of interacting FRT (FLP Recombinase Target) sites.                  
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D.1.5 Oligonucleotides used as primers for PCR amplification 
General primers: 
CMV SE  5'-GTA CAT GAC CTT ATG GGA CTT TCC-3' 
BGH AS  5'-GGC AAC TAG AAG GCA CAG TCG AGG-3' 
Bam HI - B2R SE 5'-GGATCC*ATGCTCAATGTCACCTTGC-3' 
Xho I - B2R AS  5'-CTCGAG*TTTGCTCACTGTCTGC-3' 
Bam HI - GFP SE 5'-GCTGGATCC*ATGGTGAGCAAGGGCGAGGAG-3' 
Xho I - GFP AS  5'-ACATCTCGA*GTTACTTGTACAGCTCGTCCATGCC-3' 
 
Chimera primers: 
B2eYFP SE  5'-GGACTGGGCAGGGAGCAGACAGATGGTGAGCAAGGGCGAGGAG-3' 
 
* underlined sequence represents the restriction site for the indicated restrictase. 
 
All other primers were designed following these standard rules: 
- the length of primer complementary to the template should be 18-25 nucleotides 
- the G+C content should be between 40 and 60% 
- „GC clamp” at the 3' end 
- the melting temperature was calculated by the formula: 
Tm (in C°) = 2(A+T) + 4(G+C) 
where (A + T) is the sum of the A and T residues and (G + C) is the sum of the G and C 
residues in the oligonucleotide, which should not be less than 50°C. 
 
D.1.6 Computer programs and Data analysis 
- Adobe Acrobat 7.0 Professional 
- EndNote 8.0 
- Internet (Firefox, Safari) 
- MacVector 7.2.3 
- Microsoft Office 2004 (Word, Excel, Powerpoint) 
- All data analysis was performed using GRAPHPAD PRISM for Macintosh, Version 4.0c 
(GraphPad Software, Inc., San Diego, CA, USA). Data were assessed by appropriate 
analysis of variance (ANOVA), with subsequent post hoc analysis using the Student-
Newman-Keuls test. Alternatively, paired t-tests were used as indicated. 
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D.1.7 Solutions 
Solutions used in molecular and cell biological methods 
TAE buffer    40 mM Tris, 20 mM acetate, 2 mM EDTA pH 8.3 
Loading buffer   30% (w/v) glycerol, 0.25% (w/v) bromophenol blue, 
     0.25% (w/v) xylencyanol FF, 0.25% (w/v) orange G 
SOC medium 20g/l Bacto-tryptone, 5 g/l Bacto-yeast extract, 10 mM     
MgCl2, 20 mM glucose, 10 mM NaCl, 10 mM KCl pH 7.0 
LB growth medium   10 g/l Bacto-tryptone, 5 g/l Bacto yeast extract, 10 g/l NaCl 
 
Solutions used in protein chemical methods 
RIPA buffer 50 mM Tris-HCl, 150 mM NaCl, 1% Nonident P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 2 mM EDTA, pH 7.5 
Lysis buffer 0.1% Triton X-100, 10mM Tris-HCl, 150 mM NaCl, 25 mM  
KCl, pH 7.4 
Stripping buffer (BPA assay)  50 mM glutathione, 0.3 M NaCl, 75 mM NaOH, 1% FCS 
Tris-buffered saline (TBS) buffer 50 mM Tris-base, 150 mM NaCl pH 7.5 
TBST buffer    TBS buffer with 0.1% Tween 20 
Blocking buffer    5% milk powder in TBS buffer containing 0.1% Tween 20 
MOPS SDS Running buffer  From Invitrogen  
Transfer buffer   From Invitrogen 
LDS Sample buffer   From Invitrogen 
 
 
Solutions used in pharmacological methods 
Incubation buffer 40 mM PIPES, 109 mM NaCl, 5 mM KCl, 0.1% glucose, 
0.05% BSA, 2 mM CaCl2, 1 mM MgCl2, 2mM bacitracin, 
0.8 mM 1.10-phenantroline, 100 µM captopril, pH 7.0 
Dissociation solution   0.2 M acetic acid, 0.5 M NaCl, pH 2.7 
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D.2 Methods 
D.2.1 Molecular biological methods 
D.2.1.1 Polymerase chain reaction (PCR) 
DNA Fragments were amplified and mutagenized by PCR. 
Primers were designed following these standard rules. Firstly, the length of primer 
complementary to the template should be 18-25 nucleotides to minimize problems of nonspecific 
annealing. Secondly, the G+C content should be between 40 and 60%. Thirdly, the melting 
temperature was calculated by the formula: 
 
Tm (in C°) = 2(A+T) + 4(G+C), 
 
where (A + T) is the sum of the A and T residues and (G + C) is the sum of the G and C residues 
in the oligonucleotide, which should not be less than 50°C. The designed primers were 
synthesized by Invitrogen and are listed in section D.1.5. 
Two important properties are required of a thermostable DNA polymerase used for mutagenesis 
of a plasmid template: an efficient proofreading activity and a lack of terminal transferase 
activity. Therefore, in all following reactions Pfu or Taq polymerase was used. 
 
The PCR was used for the following purposes: 
D.2.1.2 Attachment of the restriction sites 
To clone a DNA insert into a vector, both were treated with two restriction enzymes that created 
compatible ends. Whereas cloning vector pcDNA5/FRT has sites for BamHI and XhoI restriction 
endonucleases in its multiple cloning site (Fig. D-1), cleavage sites for above cited restrictases by 
DNA insert were introduced using PCR. For that pairs of primers with restriction sites for BamHI 
in the 5' region of the sense primer and for XhoI in the 5' region of the anti-sense primer (section 
D.1.5).  To improve restrictive reaction 3-4 additional base pairs (bp) were introduced at the 5' 
end of each primer (Fig. D-3). After PCR, the amplified DNA fragment was digested with the 
appropriate restriction enzymes and ligated into the multiple cloning site of the linearized vector.    
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Fig. D-3: Cloning of PCR product by addition of restriction sites (Figure from Dr. Irina Kalatskaya). 
Specific PCR primers were designed to amplify a region of interest with the Hind III (at the beginning) and 
the Xho I (at the end) recognition sequences for the restriction endonuclease included at the 5' end of the 
primer. To achieve high efficiency digestion, additional nucleotides were included on both sides of the 
restriction endonuclease sequence. 
 
D.2.1.3 Site-directed mutagenesis 
We used site-directed mutagenesis to design the constructs that were used in section E.2 and E.3. 
For the site-directed mutagenesis of the B2R the so called “megaprimer method” was applied. 
This method uses three oligonucleotide primers and two rounds of PCR. One of the 
oligonucleotides is mutagenic, containing the desired base substitution(s), and the other two are 
forward and reverse primers that lie upstream and downstream from the binding site for the 
mutagenic oligonucleotide. The flanking primers were complementary to sequences in the cloned 
gene or to adjacent vector sequences. The mutagenic primer was oriented towards the nearer of 
the flanking primers so that the length of the megaprimer was kept to a minimum (Fig. D-4, A). 
The mutagenic oligonucleotide was designed to a length of 20-35 bases, depending on how many 
bases had to be changed for the desired mutations. The mutation, and therefore the mismatched 
region of the primer, was located in the middle of the primer with at least 10-15 correctly 
matched bp on each side of the mismatched region (for less than 3 miss-matching bp).  
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Fig. D-4: The principle of the “megaprimer method” (Figure from Dr. Irina Kalatskaya). 
A) PCR1 was performed with a mutagenic primer and an outside primer (primer 1) to generate and amplify a 
double-stranded megaprimer. 
B) The “megaprimer” was purified and used with an additional outside primer (primer 2) in PCR2 to obtain 
the desired full-length mutant. To increase the efficacy of PCR2, the primer 1 was added to the reaction 
mixture and as template was wild type DNA embedded into another vector not containing a site for primer 1. 
 
The first PCR was performed according to Table 1 using the mutagenic internal primer designed 
as it was described before and the first flanking primer (Figure D-4, A). 
 
Tab. 1. Composition of the first PCR used in the megaprimer method. 
Components Working concentration Stock Volume 
Template 1 0.1 µg - - 
PCR buffer 1× 10× 3 µl 
Pfu polymerase 0.05 U/µl 2.5 U/µl 0.6 µl 
Primer 1 0.2 µM 10 µM 0.6 µl 
Mutagenic primer 0.2 µM 10 µM 0.6 µl 
DMSO 1× 5× 3 µl 
dNTP 0.8 mM 10 mM 2.4 µl 
H2O - - to 30 µl 
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The first PCR was carried out according to the following cycle program 1: 
Denaturation  92°C 3 min 
Cycle (25 ×) 
Denaturation  92°C 30 sec 
Annealing  50°C 30 sec 
Elongation  72°C 60 sec/1000 bp 
Elongation  72°C 10 min 
Storage   4°C ∞ 
 
The product of this first PCR – the “megaprimer” – was purified as described in section D.2.1.7. 
In the first and second PCR the used wild type templates were embedded into two different 
vectors. In this case the usage of primer 1 in the PCR 2 led to preferable amplification of the 
newly synthesized mutated DNA as to amplification of the wild type template (Fig. D-4, B). The 
reaction mixture of the PCR 2 was prepared using Template 2 (0.1 µg), Primer 1/Primer 2 (0.2 
µM) and Megaprimer (50 ng/µl). The same amounts of Pfu polymerase, DMSO, dNTP and H2O 
were used as in Table 1. A longer region of the template DNA was amplified using 35× cycles, 
annealing at 53°C and the first elongation for 90 sec. The final PCR product containing the 
desired mutation was separated by gel electrophoresis (section D.2.1.3) and purified from the 
agarose gel (section D.2.1.7). 
 
D.2.1.4 Generation of the B2eYFP chimera 
The coding region of the B2R and the enhanced yellow fluorescent protein (eYFP) were fused 
using the megaprimer method in a two-step reaction. The stop codon of the B2R was omitted, 
whereas the first methionine of the eYFP-construct was included. A 43-bp chimera-primer 
containing the 22 bp encoding the C-terminal amino acids of B2R followed by 21 bp encoding the 
proximal end of the eYFP gene (Fig. D-5, A). As described before, a megaprimer was prepared in 
the PCR 1 according to Table 1 using the pEYFPC-3 (CLONTECH) gene as template and 
chimera primer (Fig. D-5, B). 
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Fig. D-5: Generation of the eYFP chimera (Figure from Dr. Irina Kalatskaya). 
A) PCR 1 was performed with a mutagenic chimera primer and the reverse primer for eYFP (primer 1) to 
generate and amplify a double-stranded megaprimer. 
B) The megaprimer was purified and used with the forward primer for B2R (primer 2) in PCR 2 to obtain the 
desired full-length chimera mutant. 
 
The first PCR reaction was carried out using cycle program 1 (D.2.1.3) besides 10 min for the 
first denaturation instead of 3 min. The megaprimer was purified by agarose gel electrophoresis 
and extracted using a gel extraction kit. 
 
A second PCR mixture (Figure D-5, C) contained B2R gene (0.3-0.4 µg) as the template, the 
megaprimer (5 µl) described above and the reverse primer for eYFP (0.6 µl). The amounts of 
PCR buffer, Pfu polymerase, DMSO, dNTP and H2O were the same as in Table 1. The second 
PCR reaction was carried out using the following cycle program 1 (D.2.1.3) besides 10 min for 
the first denaturation instead of 3 min, annealing performed at 45°C (instead of 50°C) and the 
first elongation for 2 min (instead of 60 sec). The final PCR product was a 1.8-kb fragment 
containing the B2R coding sequence fused to the eYFP gene. This B2eYFP fragment was 
extracted from the agarose gel (section D.2.1.7). 
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D.2.1.5 DNA cleavage with restriction endonucelases 
Optimal buffer conditions were chosen for each restriction enzyme digest according to supplier’s 
information. The reaction mixture was prepared on ice according to the protocol for DNA 
restriction mentioned below. DNA was usually digested at 37°C for about 1 h. 
 
Protocol for DNA restriction 
DNA   2 µg 
Restrictase  2 µl (2 unit) 
Buffer   2 µl 
H20   to 20 µl 
 
 
D.2.1.6 Agarose gel electrophoresis 
For preparation of the gels, agarose was dissolved in TAE buffer (D.1.7 Solutions) in a 
microwave oven. The final concentration of agarose was 0.5-2 % depending on the size of the 
separated DNA fragments. Ethidium bromide was added to a final concentration of 1 µg/ml for 
later visualization of the DNA under UV light. Loading buffer (D.1.7 Solutions) was added to the 
samples (ratio 1:5) before loading the gel in order to control the separation during the run. The 
running buffer was also TAE. Electrophoretic separation was achieved by constant currents at 5-7 
V/cm for about 30 min. The gels were observed under UV light (312 nm) and the size of the 
fragments were determined by comparing their mobility with that of DNA standards. To avoid 
DNA damage by UV radiation exposure to UV was kept as short as possible. 
 
D.2.1.7 Extraction of DNA fragments from agarose gels 
After separation of the DNA fragments by agarose gel electrophoresis, the band corresponding to 
the fragment of interest was isolated using the QIAquick gel extraction kit (Qiagen) following the 
protocol of the supplier. 
» The band of interest was cut out with a scalpel. 
» The agarose gel slice containing the DNA fragment was solubilized by addition of the buffer 
QX1 and by incubation for 10 min at 50°C. The high concentration of a chaotropic salt in buffer 
QX1 disrupts hydrogen bonding between sugars in a agarose polymer and promotes the 
dissociation of DNA binding proteins from the DNA fragments. 
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» The DNA fragment was selectively bound to a silica-gel resin in the presence of a high 
concentration of a chaotropic salts (QX1). 
» Salts were washed out by the PE buffer containing ethanol. 
» Residual PE buffer was removed by an additional centrifugation step. 
» DNA was typically eluted with 10 µl of 10 mM Tris-HCl, pH 8.5 or water, as elution is most 
efficient under low salt concentrations and basic conditions. As the pH is critical for binding and 
therefore the DNA recovery, the pH was controlled even when water was used. 
 
D.2.1.8 Ligation of DNA fragments 
The insert obtained after adding restriction sites by PCR (section D.2.1.1) and pcDNA5/FRT 
vector were cleaved with HindIII and XhoI (section D.2.1.2). A 3-5 molar excess of DNA 
fragment (estimated by intensity of the bands on the agarose gel) was added to a linearized vector 
(0.1-1.0 µM) in a final volume of 10 µl at RT. 1 µl (1 U/µl) of T4 ligase as well as 1 µl of T4 
ligase buffer were then added on ice. The ligation mixture was incubated 1 h in a water bath at 
16°C. 
 
D.2.1.9 LB growth medium and plates for culture of E. coli strains 
LB (Luria Bertani) growth medium (see Solutions D.1.7) was sterilized by autoclaving for 20 
min at a pressure of 1.2 × 105 Pa and a temperature of 121°C. Ampicillin was added to the media 
at a concentration of 50 mg/ml when the temperature was below 50°C. 15 g/l agar was added for 
the preparation of LB plates before autoclaving. For short term storage the E. coli strains were 
spread onto agar plates containing the appropriate antibiotics and then stored at 4°C. 
 
D.2.1.10  Transformation of E.coli 
Transformation of E.coli strains was performed by heat shock with slight modification of the 
supplier’s protocol. 2 µl of the ligation reaction (section D.2.1.8) or plasmid (< 0.1 µg) was added 
to 15-25 µl of competent cells (E.coli TOP 10) and mixed gently in a 1.5 ml reaction cup. After 
incubation on ice for 30 min, the cells were heat shocked for 30 sec in a water bath at 42°C 
without shaking. The tubes were immediately transferred onto ice and incubated there for another 
2 min. After addition of 100 µl of SOC medium (D.1.7 Solutions) the tube was shaken at 37°C 
for 1 h and then again placed on ice. The whole volume of the transformation mixture was spread 
on a LB plate containing 50 mg/ml ampicillin and incubated overnight at 37°C.  
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D.2.1.11  Colony-PCR 
To screen and select cell colonies that had the correct plasmid insert colony-PCR was used. This 
method is appropriate for determining whether or not a specific colony on a plate has the desired 
sequence. The reaction mixture was prepared in an application tube on ice using Primer 1 and 
Primer 2 (0.5 µM), Taq polymerase (0.05 U/µl) and H2O to 7.55 /µl. The same amount of PCR 
buffer, DMSO and dNTP as in Table 1 were used and the PCR was carried out using cycle 
program 1 (section D.2.1.3). A small part of a colony was picked from the agarose plate with a 
plastic tip and resuspended in 15 µl of reaction mixture. Usually 3-4 colonies were checked. 
Analysis of the PCR products was performed by agarose gel electrophoresis (section D.2.1.6). 
 
D.2.1.12 Plasmid preparation from E.coli 
For most purposes like testing of recombinant DNA by restriction endonuclease digestion, for 
DNA sequencing or transfection with the Flp-In system plasmid DNA was prepared from 6 ml 
overnight cultures of recombinant E.coli using the QIAprep Spin Miniprep Kit. This kit is based 
on a modified alkaline lysis procedure protocol (Birnboim and Doly, 1979) of the cell pellet. 
Bacteria were lysed under alkaline conditions in the presence of RNase A, and the lysate was 
subsequently neutralized. Afterwards, the remainder of the bacteria containing the chromosomal 
DNA was discarded by centrifugation, and the soluble plasmid DNA was selectively bound to a 
silica-gel membrane of QIAprep column which was washed twice in order to eliminate all the 
other contaminants (proteins, RNA, and low molecular weight impurities). Elution from the 
column was achieved by addition of water or 10 mM Tris-HCl, pH 8.5.  
 
D.2.1.13 Confirmation of correctness of DNA sequence 
If a new plasmid was made only by cleavage and restriction, correctness of DNA ligation was 
checked by cleavage using the same restriction nucleases. 
As the DNA-polymerases sometimes induce mistakes, after site-directed mutagenesis or 
generation of chimera, DNA sequencing was performed by a commercial service (MediGenomix, 
Martinsried, Germany). 
 
D.2.1.14  Determination of DNA concentration  
The concentration of DNA was determined spectroscopically by measuring the absorbance at 260 
nm. For a 50 µg/ml solution of dsDNA the absorption coefficient was set to be 1 (1 cm 
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pathlength) (Sambrook and Gething, 1989). 5 µl of DNA sample was dissolved in 495 µl of 
water or TAE buffer. The final concentration of DNA was calculated by the following formula: 
 
CDNA (µg/ml) = 50 µg/ml × dilution factor (×50) × OD260. 
 
The purity of the preparation was estimated by measuring the UV absorption spectrum at 260 and 
280 nm. The absorbance ratio A260nm/A280nm (between 1.8 and 2.0) provided the purity of the 
protein. 
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D.2.2 Cell culture methods 
D.2.2.1 Culture of mammalian cells 
HEK 293 cells were grown as adherent monolayers in DMEM supplemented with 10% fetal calf 
serum (FCS) and 100 Unit•ml-1/100 µg•ml-1 penicillin-streptomycin at 37°C, 5% CO2/air. HEK 
293 cells double every 18-24 h, under optimal conditions. They were normally subcultured twice 
a week according to the following procedure: The old medium was removed and the cells were 
washed twice with PBS. Thereafter, the appropriate volume of EDTA-trypsin solution was added 
to the culture flasks and the cells were incubated for 5 min at 37°C. Trypsinization was stopped 
by resuspending the cells in complete growth medium. The cells could now be plated on cell 
culture plates for experiments. For experiments that required a lot of rinsing were the plates 
shortly pretreated with 0.01% poly-D-lysine hydrobromide in PBS to improve cell adherence to 
the flask surface. 
 
D.2.2.2 Cell freezing and thawing 
To freeze the cells, they were spun down under sterile conditions for 5 min at 900 rpm. The cell 
pellet was then resuspended in cold freezing medium (DMEM with 10% FCS, penicillin-
streptomycin supplemented with 7.5% DMSO. Aliquots of 1.8 ml were quickly dispensed into 
freezing vials (4°C). The cells were stored at -80°C overnight. The next day, they were 
transferred to liquid nitrogen. 
For cell thawing a freezing vial was removed from the liquid nitrogen and put in a water bath at 
37°C. The cells were then dispensed in 5 ml of complete growth medium that was pre-incubated 
at 37°C. After approximately 1 h the medium was changed to new complete growth medium.  
 
D.2.2.3 Flp-In expression system 
We used the Flp-InTM system from Invitrogen as our expression system. It allows integration and 
expression of our gene of interest in mammalian cells at a specific genomic location. 
The Flp-InTM system contains three main components (Fig. D-6):  
» The first major component is the Flp-InTM cell line containing a single integrated FRT site (FLP 
Recombinase Target). Flp-   InTM T-RexTM-293 cell line was bought from Invitrogen. 
» The second major component is the pcDNA5/FRT (Fig. D-1) expression vector into which the  
gene of interest was cloned. Expression of the gene of interest is controlled by the CMV 
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promoter. The vector also contains a hygromycin resistance gene with FRT site, which, is part of 
the 5' coding region and lacks a promoter and the ATG initiation codon. 
» The third major component of the of the Flp-InTM system is the pOG44 (Fig. D-2) plasmid, 
which, transiently expresses the Flp recombinase under control of the CMV promoter. Flp 
recombinase is a member of the integrase family of recombinases that mediates a site-specific 
recombination between interacting DNA molecules via pairing the interacting FRT  sites. 
 
Fig. D-6. Diagram of the Flp-InTM system (Figure taken from Invitrogen). 
pUC ori: replication origin, Amp: ampicillin resistance gene, BGH pA: bovine growth hormone 
polyadenylation sites, SV40 pA: simian virus polyadenylation sites, PCMV: cytomegalovirus promoter.  
 
The pOG44 plasmid and the pcDNA5/FRT vector with the gene of interest were co-transfected 
into the Flp-InTM T-RexTM-293 cell line (Fig. D-3). Upon co-transfection, the Flp recombinase 
expressed from pOG44 mediated a homologous recombination between the FRT sites (integrated 
into the genome and on pcDNA5/FRT) such that the pcDNA5/FRT construct was inserted into 
the genome at the integrated FRT site. This insertion brought the SV40 promoter and the ATG 
initiation codon (integrated in the Flp-InTM cell line) into functional proximity with the 
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hygromycin resistance gene. Thus, stable Flp-InTM expression cell lines can be selected for 
hygromycin resistance.  
 
The wild type B2R gene and all other constructs started with the third encoded methionine (Hess 
et al., 1992), which initially was assumed to be the start codon. All receptor coding sequences 
were preceded at the N-terminus by a single hemagglutinin (HA)-tag (MGYPYDVPDYAGS), 
with the last two amino acids (Gly-Ser) of the tag being generated by the insertion of the BamHI 
site and were cloned into the HindIII and the XhoI sites of the pcDNA5/FRT vector (Fig. D-1). 
The nature of the tag did not influence the pharmacological properties of the constructs. 
 
D.2.2.4 Transfection of HEK 293 cells 
This protocol was found to be best suited for our cells: 100 µl of serum-free medium, 1.6 µg of 
pOG44, 0.4 µg of plasmid of interest and 5 µl of FuGENE HD Transfection Reagent were mixed 
in a well of 96-well plate. The mixture was incubated at 37°C for 15 min. The mixture was added 
drop wise directly to the cells (with <60% confluence) growing on 6- or 12-well plates in the 
complete DMEM medium supplemented with FCS. 
For transient transfections 2.0 µg plasmid of interest was used. This was mixed together with 100 
µl of serum-free medium and 5 µl FuGENE HD Reagent in a well of 96-well plate.  
The following day the cells were trypsinized and transferred to a 100-mm dish. After 2 days, 
hygromycin B was added to the medium at a final concentration of 250 µg/ml and selection was 
started. After another 3-5 days the medium was changed and the cells were incubated without 
hygromycin. 
Within approximately 12 days after transfection 6-20 clones were usually observed. Single clones 
were then transferred to a 12-well plate by picking with a plastic tip. When enough cells were 
available the ligand binding was estimated in a binding assay at 4°C using radiolabeled 
bradykinin ([3H]BK). Clones exhibiting similar high binding activity were considered to 
represent a single insertion of the pcDNA5/FRT vector, containing the receptor gene, at the 
recombinase target site. Cells with twice as much binding activity were presumed to have an 
additional insertion of the vector (rare), clones with less binding activity were assumed to be 
inhomogeneous and were not further propagated or reselected with hygromycin B. 
 
 
MATERIAL AND METHODS 37
D.2.3 [3H]Bradykinin binding studies 
D.2.3.1 Expression levels of constructs. 
Maximal binding of [3H]BK to confluent monolayers of HEK 293 cells, stably and isogenically 
expressing the indicated constructs, was estimated with at least 3 different clones in 24-wells 
after incubation with 200 µl of approximately 30 nM [3H]BK for 90 minutes on ice.  
 
D.2.3.2 Equilibrium binding experiments at 37°C and 4°C. 
For the determination of the equilibrium binding affinity constant Kd at 4°C and in particular at 
37°C, receptor sequestration was inhibited by pretreatment of the cell monolayers on 24-well/48-
wells with 100 µM phenyl arsine oxide (PAO) in incubation buffer for 5 min at 37°C. Thereafter, 
the cells were washed three times with ice-cold PBS, 0.3/0.2 ml of incubation buffer with 
degradation inhibitors (2 mM bacitracin, 0.8 mM 1.10-phenanthroline, and 100 µM captopril) 
containing increasing concentrations of [3H]BK (10 concentrations ranging from approximately 
0.01 nM to 50 nM) were added quickly on ice, and the cells immediately warmed up to 37°C in a 
water bath. For the determination of the affinities at 37°C the incubation was stopped after 30 
min by placing the trays on ice and rinsing the cells four times with ice-cold PBS. Surface bound 
[3H]BK (>95% of totally bound radioactivity in cells pretreated with PAO) was than dissociated 
by a 10 min incubation with 0.2 ml of an ice-cold dissociation solution, transferred to a 
scintillation vial and counted in a β-counter after addition of scintillation fluid. For determination 
of the affinities at 4°C the incubation at 37°C was followed by an additional incubation on ice. 
After 90 min these cells were also washed with ice-cold PBS and [3H]BK binding measured as 
described above. Nonspecific binding was determined in the presence of 5 µM of unlabeled BK 
and subtracted from total binding being determined with [3H]BK alone to calculate specific 
binding. 
To determine the Bmax and Kd, our data were fitted to the “One Site Binding Equation”, using 
nonlinear regression. It describes the binding of a ligand to a receptor that follows the law of 
mass action: 
Y = Bmax × X / (Kd + X)  
 
where Bmax is the maximal binding and Kd is the concentration of ligand required to reach half-
maximal binding. All data analysis was performed using GraphPad Prism version 4.0c. This 
equation describes a rectangular hyperbola or a binding isotherm (Fig. D-7). 
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Fig. D-7: Ligand concentration-receptor bound curve. 
A schematic representation of total and nonspecific radioactive ligand binding is shown. The concentration of 
free radioligand was plotted on the X-axis. Y-values reflect the total number of receptors expressed in cpm, 
sites/cell or fmol/mg protein. Nonspecific binding is usually linear with the concentration of radioligand. 
 
Maximal binding capacities of the stable clones (Bmax) were either calculated from the 
equilibrium binding curves or estimated by incubation of the cells on ice with a saturating 
concentration of  [3H]BK (30 nM). 
 
D.2.3.3 Competitive inhibition [3H]BK binding to cold drugs.  
Confluent monolayer in 96-well plates were washed with ice-cold PBS and incubated on ice with 
100 µl incubation buffer (D.1.7 Solutions) containing 2 nM [3H]BK and increasing 
concentrations (10-11 – 10-5 M) of unlabeled BK, icatibant, or B9430. After 90 min the cells were 
rinsed with ice-cold PBS and treated for 10 min on ice with 200 µl dissociation solution. The 
supernatants containing the dissociated, formerly surface bound [3H]BK was thereafter 
transferred to scintillation vials and counted after addition of scintillation fluid in a β-counter. 
Non-specific binding was measured in the presence of 5 µM unlabeled BK.  
 
D.2.4 Determination of second messengers after Gq/11 activation 
D.2.4.1 Measurement of total inositol phosphate (IP) release 
80% confluent cell-monolayers of stably transfected HEK 293 cells on 12-well dishes were 
labeled overnight with 1 µCi [3H]-inositol/ml in 0.5 ml DMEM containing fresh FCS and 
penicillin/streptomycin. The next day, the monolayers were placed on ice, rinsed three times with 
ice-cold PBS and pre-incubated on ice in incubation buffer supplemented with 50 mM LiCl with 
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or without addition of increasing concentrations (10-11 – 10-5 M) of BK, icatibant and B9430. 
After 90 min the accumulation was started by placing the cells in a water bath at 37°C. The 
stimulation was terminated after 30 min by exchanging the buffer for 0.75 ml of ice-cold 20 mM 
formic acid solution and putting the tray on ice for additional 30 min. Subsequently, the 
supernatant was combined with another 0.75 ml of formic acid solution followed by 0.2 ml of a 
3% ammonium hydroxide solution. The mixtures were applied directly off the trays to AG 1-X8 
anion exchange columns (2-ml volume). The columns were washed with 1 ml of 1.8% 
ammonium hydroxide and 9 ml of 60 mM sodium formate/5 mM tetraborate buffer followed by 
0.5 ml 4 M ammonium formate/0.2 M formic acid. Total inositol phosphates were finally eluted 
in 3 ml of the latter buffer and counted in β-counter after addition of scintillation liquid. The 
[3H]BK binding was measured in parallel by incubation of the cells on ice with a saturating 
concentration of [3H]BK (10nM). 
 
D.2.4.2 Basal and stimulated IP accumulation in fibroblasts HF-15 after pro-longed 
stimulation 
Fibroblasts HF-15 were incubated with 1 µCi [3H]-inositol/ml in 500 µl of medium containing 
10% fetal calf serum that was pretreated for 2 h at 54°C (heat inactivated serum). At the same 
time were the cells stimulated with 10 µM BK, 5 µM B9430 or 5 µM icatibant, respectively 
overnight. The next day stimulation was performed with or without addition of increasing 
concentrations (10-11 – 10-6 M) of BK in the presence of 50 mM LiCl for 30 min at 37°C (as 
described in section D.2.4.1). 
 
D.2.4.3 Time and Concentration-dependent release of intracellular [Ca2+]. 
Nearly confluent monolayers on 96-well plates were washed twice with PBS and incubated 1 h in 
cell culture medium containing dye loading buffer (containing HBSS, Probenicid, CaDye) at 
37°C in the incubator to allow uptake. Thereafter, plates were placed in a Cellux reader and 
stimulated after recording the baseline for ten seconds by addition of increasing concentrations of 
BK, B9430 or icatibant (seven concentrations starting from 0.01 nM to 10 µM). The absorption 
was recorded every 1.5 sec for 5 min. For the calculation of Emax the baseline was subtracted. 
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D.2.5 Receptor sequestration and ligand internalization assays 
D.2.5.1 Down-regulation assay 
The HEK 293 cells were plated on 48-well dishes with DMEM containing fresh FCS and 
penicillin/streptomycin. Confluent cell monolayers in 48-well plates were incubated with 10 µM 
BK, 5 µM icatibant or 5 µM B9430 in 500 µl of medium containing 10% fetal calf serum that 
was pretreated for 2 h at 60°C to reduce its proteolytic activity (inactivated serum, 60°C). At the 
indicated times, both bound and free unlabeled ligand was removed by treating the cell 
monolayers immediately with ice-cold dissociation solution for 10 min and rinsing them with 
PBS. Alternatively, for recovery experiments the cells were first washed with 1 ml of cell culture 
medium at 37°C containing fresh (to promote degradation of residual BK) fetal calf serum, 
incubated in another 1 ml of medium for 1 h at 37°C and then treated with the dissociation 
solution. To measure the remaining surface binding all cells were incubated with 2 nM [3H]BK in 
incubation buffer on ice. After 90 min, free [3H]BK was removed by rinsing the cells with PBS 
and surface-bound [3H]BK was determined after dissociation with ice-cold dissociation solution 
as described above. Non-specific binding was measured in the presence of 5 µM unlabeled BK. 
 
D.2.5.2 Internalization of [3H]BK or [3H]NPC17331. 
Cells on 24-well plates were rinsed three times with PBS and incubated with 0.2 ml of 2 nM 
[3H]BK or 2 nM [3H]NPC17331 respectively in incubation buffer for 90 min on ice in order to 
obtain equilibrium binding. [3H]ligand internalization was started by placing the plates in a water 
bath at 37°C. The internalization process was stopped at the indicated times by putting the plates 
back on ice and washing the cells four times with ice-cold PBS. Subsequently, surface bound 
[3H]ligand was dissociated by incubating the cell monolayers for 10 min with 0.2 ml of ice-cold 
dissociation solution. The remaining monolayer with internalized [3H]ligand was lysed in 0.2 ml 
0.3 M NaOH and transferred with another 0.2 ml water to a scintillation vial. The radioactivity of 
both samples was determined in a β-counter after addition of scintillation fluid. Non-receptor-
mediated [3H]ligand surface binding and internalization were determined in the presence of 5 µM 
unlabeled BK and subtracted from total binding to calculate the specific values. Internalization 
was expressed as amount of internalized [3H]ligand as a percentage of the combined amounts of 
internalized and surface bound [3H]ligand. 
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D.2.6 Protein biochemical methods 
D.2.6.1 SDS-polyacrylamid-gelelectrophoresis 
The separation of proteins from lysates of eukaryotic cells was performed with discontinuous 
electrophoresis (Laemmli, 1970). The presence of SDS in the gels and buffer results in 
denaturation of the proteins. The separation in according to their molecular weight is due to the 
attachment of detergents, which provide a negative charge on the proteins. SDS-PAGE gel 
electrophoresis was performed under reducing conditions in precast 4-12 % minigels applying the 
NuPAGE Bis-Tris-buffer system using XCell SureLock Mini-cell (invitrogen). For detection of 
the protein of interest, they were transferred after electrophoresis on nitrocellulose membranes, 
once again using the XCell SureLockTM Mini-cell. The membranes were then incubated in 
blocking buffer (D.1.7 Solutions) at RT for 1 h or overnight at 4°C to block nonspecific binding 
sites on the membrane. The appropriate primary antibody was added at RT for 2 h or overnight at 
4°C in fresh blocking buffer. The unbound antibodies were removed by rinsing with TBST buffer 
(D.1.7 Solutions) before adding the corresponding secondary horseradish peroxidase-labeled 
(HRP) antibody at RT for 1 h. For detection of the proteins the Western Blot Chemiluminescence 
Reagent Plus (Perkin-Elmer) was used and then exposed to the film. 
 
D.2.6.2 Immunoblotting after solubilization with RIPA 
Monolayers in six-well trays were washed three times with PBS and solubilized in RIPA buffer 
(D.1.7 Solutions) including 0.5 mM Pefabloc SC and 10 µM each 1.10-phenathroline, aprotinin, 
leupeptin and pepstatin A for 30 min at 4°C with gentle agitation. The lysate was centrifuged at 
6.240 x g for 15 min at 4°C. The supernatant (protein concentration ∼1 mg/ml) was mixed with 
LDS sample buffer and incubated 10 min at 70°C. The proteins (∼15 µg total protein/lane) were 
run on 4 - 12% SDS-polyacrylamide gels. The following protein transfer and antibody detection 
was performed as described in section D.2.6.1.  
 
D.2.6.3 Protein levels of B2 receptor during prolonged agonist/antagonist treatment 
Cells were plated on 6-well plates. When the cells were approximately 80% confluent the 
medium was changed to a medium supplemented with 10% fetal calf serum that was pretreated 
for 2 h at 60°C to reduce its proteolytic activity (inactivated serum). The cells were treated for 1 
or 16 hours with 10 µM BK, 5 µM B9430 and 5 µM icatibant. After incubation the plates were 
washed three times with PBS. The cells were solubilized in Lysis buffer (D.1.7 Solutions) 
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including 0.5 mM Pefabloc SC and 10 µM each of 1.10-phenanthroline, aprotinin, leupeptin and 
pepstatin A. The lysates were centrifuged for 20 min at 13.000 rpm at 4°C. The EZview Red 
Anti-HA Affinity Gel beads (SIGMA) were equilibrated twice with Lysis buffer without 
inhibitors. 200 µl of supernatant was incubated with the equilibrated EZview Red Anti-HA 
Affinity Gel beads for 1 hour at 4°C. The mixture was then washed three times with Lysis buffer 
without inhibitors, resuspended in 40 µl 1X sample buffer with 0.1 M DTT, and incubated for 6 
min at 95°C. Following electrophoresis and antibody detection was performed as described in 
section D.2.6.1.  
 
D.2.6.4 MAPK kinases ERK1/2 
For the detection of phospho-ERK1/2 and total-ERK confluent cells on 6-well plates were 
incubated for 24 hours in DMEM medium supplemented with reduced serum (0.5 % FCS). The 
next day the cells were washed three times with PBS and incubated on ice with 1 ml of 
incubation buffer containing 2 mM bacitracin, 0.8 mM 1.10-phenanthroline and 100 µM 
captopril pH 7.4 ± 1 µM of BK, icatibant and B9430. After 30 minutes stimulation was started by 
placing the trays in a water bath at 37°C for 10 min. The monolayers were then washed with ice-
cold PBS and scraped off in 0.3 ml Complete Lysis-M EDTA-Free Lysis Buffer (Roche, 
Mannheim, Germany) containing a protease inhibitor cocktail (complete Mini, EDTA-free; 
Roche). The phosphatase inhibitors, 25 mM NaF, 1 mM sodium orthovanadate were also added. 
The lysates were centrifuged at 14000 rpm in a microfuge for 10 min. 30 µl of supernatant was 
taken and transferred to a new microtube. 10 µl of 4X NuPAGE LDS Sample Buffer was added 
containing 0.1 M DTT. Probes were briely vortexed and then heated at 99°C for 6 min. The probe 
samples were centrifuged for 2 min and 20 µl was loaded on a 4-12% SDS-PAGE gel. The 
separated proteins were transferred to a 0.45-µm nitrocellulose membrane. The following 
procedure was according to the Snap i.d. protein detection system (Millipore). The unspecific 
sites were blocked for 10 min in blocking buffer. The primary antibodies total-ERK (monoclonal, 
Cell Signaling, dilution 1/2000) and phospho-ERK1/2 (monoclonal, Cell Signaling, dilution 
1/2000) were added for 10 min in 0.1% milk powder in TBST. The membranes were washed 
three times for with TBST before adding the corresponding secondary peroxidase-labeled horse 
anti-mouse Ig (1:2000) for 10 min in 0.1% milk powder in TBST. The antibodies were then 
revealed by Western Blot Chemiluminescence Reagent Plus. 
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D.2.6.5 Biotinylation Protection Assay 
Confluent cells were washed twice with ice cold PBS and subsequently incubated with 0.3 mg/ml 
disulfide-cleavable sulfo-NHS-SS-Biotin (Pierce) in PBS for 30 min at 4°C. After rinsing twice 
with ice cold Tris-buffered saline (TBS) to quench the biotinylation reaction, cells were 
equilibrated in OPTI MEM I (Invitrogen) for 30 min at 37°C and further incubated in the absence 
(NS = non-stimulated) or presence of 10 µM bradykinin, 5 µM B9430 and 5 µM icatibant. After 
rinsing with ice cold TBS all cells except those labeled “Total” were stripped with Stripping 
buffer (D.1.7 Solutions) for 30 min at 4°C. Glutathione was quenched with 50 mM 
iodoacetamide and 1% BSA for 20 min. at 4°C. All cells were washed twice with ice cold PBS 
and lysed with Lysis buffer  containing protease inhibitors (0.5 mM Pefabloc SC and 10 µM each 
1.10-phenanthroline, aprotinin, leupeptin and pepstatin A). Lysates were centrifuged for 15 min. 
with 14.000 rpm at 4°C in a microfuge, the supernatant was added to anti-HA high affinity matrix 
(SIGMA) pre-equilibrated with extraction buffer, and incubated with gentle mixing for 1 hour at 
4°C. Subsequently, the matrix was washed extensively with extraction buffer and denaturated 
with NuPAGE LDS sample buffer (Invitrogen) for 5 min. at 95°C without reducing agent. 
Proteins were fractionated by SDS polyacrylamide gel electrophoresis, transferred to 
nitrocellulose membrane and blocked for 1 hour in blocking buffer. Biotinylated proteins were 
detected by the Vectastain avidin-biotinylated enzyme complex immuno-peroxidase reagent 
(Vector Laboratories) and developed with Western Blot Chemiluminescence Reagent Plus. 
 
D.2.7 Receptor phosphorylation 
Confluent cells on 6-well plates were washed twice with phosphate-free DMEM, incubated for 3 
h at 37 °C in the same medium, and labeled with 0.2 mCi/ml [32P]orthophosphate for 10-12 h. 
After a 5-min exposure to 1 µM BK at 37 °C, cells were solubilized in 0.5 ml RIPA buffer 
supplemented with 0.5 mM Pefabloc SC and 10 µM each 1,10 phenanthroline, aprotinin, 
leupeptin, and pepstatin A and phosphatase inhibitors (25 mM NaF, 1 mM sodium orthovanadate, 
0.3 µM okadaic acid) for 1 h at 4°C with gentle rocking. The lysate was centrifuged at 6.240 × g 
for 20 min at 4 °C. The supernatant (0.5 ml with ∼ 1.5 mg of total protein) was incubated with 35 
µl of protein G-agarose and 2.5 µl of antiserum AS346 for 3 h at 4 °C. The mixture was then 
washed twice with RIPA buffer and once with distilled water, resuspended in 30 µl of LDS 
sample buffer, and incubated 6 min at 95 °C. Following electrophoresis on 10% SDS-
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polyacrylamide gels, the fractionated proteins were electroblotted onto 0.45-µm nitrocellulose. 
The proteins of interest were identified by autoradiography. 
 
D.2.8 Epifluorescence microscopy 
HEK 293 cells with stable tetracycline-inducible expression of the indicated receptor-eYFP 
(enhanced yellow fluorescent protein) fusion constructs were seeded on poly-Lysine-treated 
chamber-slides (Nunc, Langerselbold, Germany). After 24 - 48 h the culture medium was 
exchange for OPTI-MEM (Invitrogen) and receptor expression induced by addition of 
tetracycline. After 16 h induction cells were treated either with vehicle or 1 µM of the indicated 
compounds for 30 min at 37°C. Images were taken halfway through the cells with an 
epifluorescence microscope (Olympus X70) with z-stack mechanisms using a 60x/1.4 oil 
immersion objective with no zoom.  
 
D.2.9 Determination of the protein concentration 
Total protein was quantified with the Micro BSA Protein Assay reagent kit from Pierce using 
BSA as standard.  
 
 
 
 
 
 
 
 
 
 RESULTS 45
E RESULTS 
E.1 Functional selectivity of B9430 and icatibant concerning PLC activation 
receptor down-regulation, and ERK1/2 activation depends on human 
bradykinin B2 receptor density and cell type 
 
E.1.1 Expression and equilibrium dissociation constants Kd of recombinantly and 
endogenously expressed human B2R 
In order to determine the influence of the receptor density on the effects of bradykinin or the two 
pseudopeptides B9430 and icatbant (sequences shown in Tab. 2) we used two cell lines stably 
expressing the recombinant bradykinin B2 receptor (B2R). In the cell line B2wtHIGH the expression 
was under the control of the strong CMV (cytomegalovirus) promoter, resulting in the expression 
of almost 11 pmol receptor/mg proteins. In the cell line B2wtLOW with the expression under the 
control of the Pmin promoter (consisting of only the last 51 nucleotides of the CMV promoter) the 
expression was, at 2.4 pmol/mg protein, considerably lower. Through the employment of the Flp-
In system (Invitrogen) both receptor constructs were isogenically expressed, i.e. the receptor 
genes were inserted at an identical unique locus in the genome of the host HEK 293 cells. To 
compare our results with a cell line that endogenously expresses the B2R we also used the well 
established human foreskin fibroblast cell line HF-15 (Roscher et al., 1983) that in our 
experiments had a Bmax of estimated 300 fmol/mg protein (Fig. E-1). The expression level had no 
significant influence on the receptor affinity (see Table 3, page 68) as for the recombinant and the 
endogenously expressed B2R similar affinities were determined at 4°C (B2wtHIGH Kd: 2.8 ± 0.7 
nM; B2wtLOW Kd: 2.0 ± 0.2 nM) or have been published (fibroblast Kd: 4.6 nM ± 0.5 nM) 
(Roscher et al., 1983). 
 
Tab. 2: Sequences of BK and pseudopeptides  
BK:   Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
Icatibant:                  DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg 
B9430:     DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg 
 
Hyp, trans-4-hydroxyproline; Oic, octahydroindole-2-carboxylic acid; Igl, α-(2-indanyl)glycine; Thi, β-(2-
thienyl)-alanine; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
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Fig. E-1: Bradykinin B2 receptor expression levels in B2wtHIGH and B2wtLOW and B2R in foreskin fibroblasts.  
Maximal [3H]BK binding Bmax of HEK 293 cells isogenically and stably expressing high (B2wtHIGH) or low 
(B2wtLOW) amounts of recombinant receptor and of endogenously expressing foreskin fibroblasts HF-15 was 
determined with approximately 30 nM [3H]BK on ice as described in „Materials and Methods“. The columns 
represent the mean ± SEM of at least four binding experiments.  The receptor expression in B2wtHIGH was 
under control of the CMV-promoter, whereas in B2wtLOW the weaker Pmin promoter was used. 
 
E.1.2 Binding affinities and potencies of (pseudo)peptides 
The binding affinities of the two pseudopeptides icatibant and B9430 that differ from BK through 
the insertion of several non naturally occurring amino acids (see Tab. 2) were determined in 
comparison with BK in a competition experiment with [3H]BK (Fig. E-2-A). Both compounds 
displaced the specific binding of 2 nM [3H]BK with low IC50-values (B9430, 15.94 ± 0.03 nM; 
icatibant, 13.86 ± 0.03 nM; n = 4). The IC50-value obtained for BK was 8.32 ± 0.03 nM (n = 4).  
Stimulation of the B2R leads to the activation of phospholipase C via G protein Gq/11 
resulting in the release of inositoltrisphosphate. Stimulation of B2wtHIGH with increasing 
concentrations of BK resulted in a sigmoid stimulation curve of inositolphosphate (IP) 
accumulation with a maximum 12-fold increase over basal IP activity, determined as amount of 
IP in cells kept on ice (Fig. E-2-B). The compounds icatibant and B9430, formally known as 
antagonists, acted when added to the B2wtHIGH as partial agonists with an Emax of 4-fold 
(icatibant) and 7-fold (B9430) stimulation over basal thus displaying 60% and 30% of the 
efficacy, respectively, of BK. The potencies for B9430 15.50 ± 0.11 nM and icatibant 17.68 ± 
0.12 nM) (n = 4) reflected well their affinities as determined from the competition binding assay 
despite the different temperature conditions of both assays. The potency for BK (0.79 ± 0.34 nM) 
differed from its affinity (8.32 ± 0.03 nM). 
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Fig. E-2: Competition inhibition of (pseudo)peptides and concentration-response IP assay in B2wtHIGH.  
(A) Competitive inhibition of 2 nM [3H]BK binding by unlabeled (pseudo)peptides. The IC50 values (BK 8.32 
± 0.03 nM, B9430 15.94 ± 0.03 nM or icatibant 13.86 ± 0.03nM) are the means ± SEM of 4 experiments done 
in duplicates. (B) Potencies for B2wtHIGH. 12-well plates were incubated overnight with 0.5 µCi [3H]inositol  
in 0.5 ml in medium. Stimulation was performed with or without addition of increasing concentrations (10-11 
– 10-5 M) of BK, icatibant or B9430 in the presence of 50 mM LiCl for 30 min at 37°C as described in 
„Materials and Methods“. One representative experiment out of three done in duplicates is shown. The EC50 
values obtained from three independent experiments: BK 0.79 ± 0.34 nM, B9430 15.50 ± 0.11 nM, icatibant 
17.68 ± 0.12 nM . 
 
E.1.3 Lower receptor expression levels turn partial agonists in antagonists 
As the partial agonism (seen in Fig. E-2, B) might have been due to the high receptor 
overexpression we took a closer look at the influence of receptor density on this property. In fact, 
in the lower expressing B2wtLOW and in the endogenously expressing fibroblasts HF-15, icatibant 
and B9430 no longer acted as partial agonists even at a concentration of 1 µM (Fig. E-3). They 
were not able to significantly stimulate IP accumulation in these cells, demonstrating that their 
partial agonism can only be observed with high receptor overexpression. 
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Fig. E-3: Basal and stimulated accumulation of total inositol phosphates. 
HEK 293 cell lines B2wtHIGH and B2RLOW and foreskin fibroblasts HF-15 in 12-well plates were incubated 
overnight with 0.5 µCi [3H]inositol in 0.5 ml medium. Stimulation was performed in the presence of 50 mM 
LiCl and 1 µM BK, B9430 and icatibant for 30 min at 37°C as described in „Materials and Methods“. Each 
value represents the mean ± SEM of at least three independent experiments done in triplicates, given as fold 
over the IP content of non-stimulated but otherwise identically treated control cells that had remained on ice. 
 
E.1.4 Real-time determination of intracellular Ca2+ mobilization. 
The determination of IP accumulation requires stimulation of the cells in the presence of 50 mM 
LiCl as a phosphatase inhibitor for 30 min to obtain a clear specific signal. In interpreting how a 
receptor interacts with its cognate G protein, a process that is supposed to happen within seconds, 
this method may not be optimal, as the long stimulation time might diffuse the real kind of 
interaction between receptor and G protein. We therefore decided to use real-time recording of 
the Ca2+ mobilization to determine the effects of stimulation with BK and the pseudo-peptides on 
the different cell lines. 
In B2wtHIGH addition of 1 µM BK resulted rapidly in a strong transient signal that decreased 
within one minute but stayed clearly above the basal level during the recording time of 5 min 
(Fig. E-4, left). Both pseudopeptides also generated a distinct signal that was transient and 
returned to the basal level within 1 min. Interestingly, the relative heights of the peaks reflected 
the efficiencies determined in the IP assay despite the quite different biological assays. In the 
lower expressing HEK 293 cells B2wtLOW, BK generated a strong signal that again did not return 
to the basal level (Fig. E-4, middle). The pseudopeptides, however produced only very poor 
signals that hardly were above the basal level. In the HF-15 cells stimulation with 1 µM BK 
produced a strong transient signal that within 1 min returned almost completely to the basal level, 
whereas the two pseudopeptides did not have any stimulating effect in these cells (Fig. E-4, 
right).  
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Fig. E-4: Time-dependent pseudo peptide stimulated rise in intracellular [Ca2+] in different cell lines. 
Cells in 96-well plates were incubated with dye loading buffer (containing HBSS, Probenicid, CaDye) for 1 h 
at 37°C. After recording the baseline for 10 seconds the (pseudo)peptides were added (1 µM BK, 0.6 µM 
B9430, or 1 µM icatibant) and Ca2+ mobilization was recorded every 1.5 sec for 5 min in a Cellux reader 
(Perkin-Elmer). (RFU, relative fluorescence units) 
 
 
E.1.5 Concentration-dependent rise in intracellular [Ca2+]. 
The potencies of the (pseudo)peptides concerning the release of Ca2+ were determined (Fig. E-5). 
The EC50-values of calcium release determined with different BK concentrations were: B2wtHIGH: 
0.12±0.11 nM, B2wtLOW: 0.34±0.09 nM; HF-15: 3.27±0.23 nM (n = 4). The results for the high 
and low expressed wild type are more or less in agreement with the EC50-values obtained from 
the accumulation of inositolphosphates B2wtHIGH: 0.79±0.34 nM, B2wtLOW: 0.67±0.22 nM 
(Tab.3). The EC-value (1.29±0.21 nM) obtained from the accumulation of IP for HF-15 has been 
determined once (concentration-response curve is not shown). But as seen in Fig. E-5 the EC-
values for B9430 and icatibant on Ca2+ were shifted a lot in this assay compared to the EC-values 
obtained from the IP accumulation.  
 
 
Fig. E-5: Concentration-dependent rise in intracellular [Ca2+]. 
Cells in 96-well plates were incubated with dye loading buffer (containing HBSS, Probenicid, CaDye) for 1 h 
at 37°C. After recording the baseline for 10 seconds increasing concentrations (10-12 – 10-5 M) were added of 
BK (□), B9430 (), and icatibant (Ο) and Ca2+ mobilization was recorded every 1.5 sec in a Cellux reader 
(PerkinElmer) for 5 min. The peaks of the curves obtained for each concentration were used to calculate 
EC50-values. Each point represents the mean ± SEM from four experiments done in duplicates. (RFU, relative 
fluorescence units). 
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E.1.6 Effect of long-term stimulation on recombinantly expressed B2R depends on 
receptor density 
As was seen for B2wtHIGH, icatibant and B9430 were able to induce an increase in IP (and hence 
increase of intracellular Ca2+) under certain circumstances. To investigate whether their agonistic 
activity was limited only to G protein activation, we next compared the effect of a long-term 
incubation with BK, icatibant or B9430 on the number of surface B2R, to determine whether the 
pseudopeptides are able to induce down-regulation of the B2R. 
Upon BK stimulation a strong reduction in [3H]BK surface binding was detected, approx. 60 % 
after 16 hours (Fig. E-6, left). On the other hand, B9340 showed only poorly, and icatibant 
showed no significant effect at all on the amount of cell surface binding. In contrast, there was a 
strong effect of BK but also of B9430 stimulation on surface binding in B2wtLOW. Within two 
hours binding was reduced to 20% for BK and to 35% by incubation with B9340 (Fig. E-6, 
right). Icatibant again had no significant effect. 
 
Fig. E-6: Effect of prolonged stimulation with BK, B9430 and icatibant on surface binding. 
B2wtHIGH (left) and B2wtLOW (right) were incubated with 10 µM BK or 5 µM B9430 and icatibant in medium 
at 37°C. At the times indicated, all free and bound pseudopeptides were removed with an acetic acid/NaCl 
solution. Thereafter, the remaining specific surface binding was determined with 2 nM [3H]BK at 4°C as 
described in “Materials and methods”. Symbols represent the mean ± SEM for at least three experiments 
performed in duplicates. 
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E.1.7 Effect of long-term stimulation on the sequestration and the recycling of 
endogenously expressed B2R (down-regulation assay) 
In the fibroblasts we also determined besides the effect of the pseudopeptides on the surface 
binding of B2R and whether there were differences in the recovery of binding. In order to 
measure recovery we stimulated the cells for the indicated times, the monolayers were then 
washed and further incubated for 1 hour at 37°C in medium containing fresh FCS to promote 
degradation of residual BK and to allow recovery of binding at the cell surface. 
The B2R in fibroblasts responded to stimulation with a rapid reduction in binding of [3H]BK. 
Stimulation with 10 µM BK resulted in a reduction by 70% within 30 min that was slightly 
further decreased by a prolonged stimulation for up to 8 h (Fig. E-7, left). Prolonged stimulation 
also greatly reduced the recovery at the cell surface when the ligand was removed, suggesting 
that under these conditions most loss of binding is irreversible. 
As shown for cell line B2wtLOW, compound B9430 was able to induce a fast and strong binding 
reduction of the B2R. This effect of B9430 was also detected in the fibroblasts (reducing binding 
even stronger than BK) (Fig. E-7, middle). The recovery of binding was similar to that seen after 
BK stimulation. In contrast to its effect on the recombinant cell lines, icatibant was able to induce 
significant binding reduction in the fibroblasts, more than 40% reduction after 30 min and almost 
60% after 8 h (Fig. E-7, right). The reduction of binding after stimulation with icatibant displayed 
a fairly strong potential to be recovered. 
 
Fig. E-7: Surface binding and recovery upon BK, B9430 and icatibant stimulation in foreskin fibroblasts. 
Foreskin fibroblasts HF-15 were incubated with 10 µM BK (left), 5 µM B9430 (middle) or icatibant (right) in 
medium at 37°C as described in “Materials and methods”. At the times indicated, the cells were either 
immediately treated with acetic acid/NaCl solution to remove bound and free peptide (open columns) or first 
washed with 1 ml of cell culture medium at 37°C containing fetal calf serum and incubated in another 1 ml of 
medium for 1 h at 37°C (to promote dissociation and degradation of bound peptides) and then treated with the 
acetic acid/NaCl solution (dark columns). The remaining specific surface binding was determined with 2 nM 
[3H]BK at 4°C as described in the “Materials and methods”. Symbols represent the mean ± SEM of three 
experiments performed in duplicates. 
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E.1.8 Protein levels of B2 receptor during prolonged agonist/antagonist treatment 
A quick reduction of surface binding was seen in B2wtLOW upon BK and B9430 stimulation, and 
in the fibroblasts B9430 induced an even stronger reduction than BK. Given this significant loss 
of surface binding upon exposure to these peptides, we investigated whether total levels of B2R 
protein are also influenced under these conditions. For this experiment we took advantage of the 
hemagglutinin tag fused to the N-terminus of the receptor. The tagged receptor was selectively 
bound upon lysis of the cells to a high-affinity hemagglutinin matrix. Thus, in an immunoblot 
(with a primary high-affinity hemagglutinin antibody) it was possible to detect all tagged 
receptors, both extracelluarly and intracellularly localized receptors, hence total B2R protein. 
Degradation of total B2wtLOW was only detected upon prolonged (16 hours) stimulation with BK 
(Fig. E-8). This decrease after 16 h of BK exposure was in agreement with the decrease of 
surface binding seen after 16 hours in the down-regulation assay. But in the down-regulation 
assay a significant loss of binding was seen already after 1 hour exposure to BK that was not the 
case on the protein level. Even though B9430 showed a 70% decrease of surface binding after 16 
hours in the down-regulation assay, no receptor degradation was detected in the immunoblot. 
Should be mentioned that this Western Blot is kind of overexposured so a comparision should be 
taken with care.  
 
 
 
 
 
 
 
 
 
 
Fig. E-8: Analysis of degradation of B2wtLOW upon ligand binding: immunoblotted with anti-HA antibody. 
HEK 293 cells expressing B2wtLOW having a hemagglutinin (HA) tag on the N-terminus were treated for 1 or 
16 hours with 10 µM BK, 5 µM B9430 and 5 µM icatibant. As a control, HEK 293 cells expressing B2wtLOW 
with a Strep-tag on the N-terminus were used. After incubation, 200 µl of each lysate were incubated with 
equilibrated EZviewTM Red Anti-HA Affinity Gel beads (SIGMA) for 1 hour at 4ºC. The immunoprecipitates 
were subjected to SDS-PAGE and Western blotting using anti-HA antibody as described in “Materials and 
Methods”. One representative experiment out of three is shown. 
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E.1.9 Receptor localization studies using eYFP-constructs 
Our next approach to determine the localization of B2wtLOW upon ligand stimulation was to use 
epifluorescence microscopy. We visualized the localization of the receptor constructs by eYFP 
(enhanced yellow fluorescent protein) genetically fused to their C-termini. HEK 293 cells stably 
expressing the construct of YFP fused to the C-terminus of B2wt (B2wtLOW-eYFP) under the 
control of the Pmin promoter were used for this purpose. B2wtLOW-eYFP was located almost 
exclusively at the membrane without stimulation (Fig. E-9). Upon BK stimulation the receptors 
were found in intracellular vesicles of various sizes. On the other hand, after challenge with 
icatibant and B9430, no intracellular localization of receptors could be detected. Even though a 
strong reduction in binding was seen after B9430 stimulation of B2wtLOW in the down-regulation 
assay (E-6), the two latter assays performed (degradation of total B2wtLOW and here 
epifluorescence microscopy) did not display any degradation or intracellular localization of 
B2wtLOW upon B9430 stimulation. Therefore we set out to perform one more assay where 
intracellular receptors can be detected, namely the biotinylation protection assay (BPA). 
                           NS       BK 
                           B9430 Icatibant 
 
Fig. E-9: Localization of wild type-eYFP fusion protein by epifluorescence microscopy. 
HEK 293 cells stably expressing the B2wtLOW-eYFP construct were incubated in the absence (NS = 
nonstimulated) or in the presence of 5 µM BK, B9430 and icatibant respectively for 1 h at 37°C and 
examined by epifluorescence microscopy. 
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E.1.10 Biotinylation Protection Assay 
With the biotinylation protection assay (BPA) surface receptors (total) and intracellular receptors 
could be localized. The cell surface receptors were labeled with a membrane-impermeable biotin 
derivate. Internalized receptors were then selectively monitored by their protection from 
extracellular stripping with a reducing agent. Once again, B2wtLOW could be intracellularly 
detected, but only upon BK stimulation (Fig. E-10). Upon icatibant and B9430 stimulation no 
intracellularly localized receptors were observed. 
 
 
 
 
 
 
 
 
 
 
Fig. E-10: Ligand-dependent receptor endocytosis as determined by BPA. 
HEK 293 cells stably expressing B2R (B2wtLOW) having a hemagglutinin tag at the N-terminus were labeled at 
4ºC with a biotin reagent containing a reducible linker (total). The two first lanes serving as controls were 
then incubated with phenyl arsine oxide for 5 min at 37 ºC (to block receptor sequestration) and then 
incubated with BK for 1 h at 37ºC. The cells for the other lanes were incubated in the absence (NS) or 
presence of 10 µM BK, 5 µM B9430 or 5 µM icatibant for 1 hour at 37 ºC. All the cells besides total were 
subsequently stripped with glutathione (strip). The receptors were immunoprecipitated with Anti-HA agarose 
beads and visualized by Vectastin followed by development with ECL reagents as described for biotinylation 
protection assay under “Materials and Methods”. One representative experiment out of three is shown. 
 
B9430 induced a loss of surface binding as seen in the down-regulation assay. But the binding 
assay in the down-regulation assay was performed only with one non-saturating concentration of 
[3H]BK (2nM), as this ligand is quite expensive. As three additional assays could not display 
receptor localization in intracellular compartments upon B9430 stimulation, ligand-induced 
receptor sequestration as the cause for this reduction in binding could be excluded. However, a 
decrease in B2R receptor affinity induced by pre-stimulation with B9430 could be a possible 
explanation for these discrepancies. To test this hypothesis, we performed equilibrium binding 
curves and scatchard plot analyses to determine receptor affinities.  
TOTAL STRIP NS BK ICATIBANT B9430 
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E.1.11 Binding of [3H]BK to B2wtLOW after long-term treatment with BK, icatibant and 
B9430.  
Cells were pre-incubated with the indicated ligands overnight followed by determination of 
equilibrium binding receptor affinity and Bmax at 4°C. Determination of specific binding is shown 
in Fig. E-11, A. Scatchard plots of the data are shown in  Fig. E-11, B. The scatchard plot showed 
a shift in receptor affinity upon prolonged stimulation with B9430, indicated by the slope of the 
line. The Kd values shifted from 7.6±2.1 nM (basal, control cells not pre-incubated with ligand) 
to 31.2±20.0 nM (cells pre-incubated with B9430). The surface binding (Bmax) remained almost 
the same 9.6±2.4 pmol/mg protein (basal) and 9.4±2.3 pmol/mg protein (B9430). The Kd and 
Bmax value for BK-treated cells was 7.7±3.5 nM and 0.86±0.25 pmol/mg protein, respective 
values for icatibant were 8.7±4.5 nM and 8.6±2.9 pmol/mg protein. Data represent the mean ± 
SEM of four experiments performed in duplicates. 
 
Fig. E-11. Binding of [3H]BK to B2wtLOW after long-term incubation with BK, icatibant and B9430. 
(A) HEK 293 cell expressing B2wtLOW were treated for 16 hours with 10 µM BK (□), 5 µM B9430 () and 
5 µM icatibant (o) respectively. Thereafter, free and bound (pseudo)peptides were removed with acetic 
acid/NaCl solution, and the cells incubated with the increasing concentrations of [3H]BK. Nonspecific 
binding was determined in the presence of 5 µM of unlabeled BK and subtracted from total binding being 
determined with [3H]BK alone to calculate specific binding. One representative experiment out of four is 
shown. (B) Scatchard plot of the data. Lines were computed by linear regression. The Kd´s and Bmax values 
calculated from data of four experiments: in control cells (basal), the Kd was 7.6 nM and Bmax 9.6 pmol/mg 
protein, respective value for the BK-treated cells were 7.7 nM and 0.86 pmol/mg protein, for B9430 treated 
cells 31.2 nM 9.4 pmol/mg protein; and for icatibant-treated cells, 8.7 nM and 8.6 pmol/mg protein. 
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E.1.12 MAPK kinases ERK1/2 
Many GPCRs can activate the Ras/mitogen-activated protein (MAP) kinase pathway, which is 
sufficient and necessary for the control of proliferation in different cell systems (van Biesen et al., 
1996). Sequestration of GPCRs is assumed to be performed through recruitment of arrestins that 
guide them to internalization via clathrin-coated pits. Arrestins have recently been more and more 
appreciated as scaffold proteins that not only play a major role in receptor sequestration but also 
in the activation of G protein independent signaling pathways such as mitogen-activated protein 
kinase (MAPK) cascades (DeWire et al., 2007). Since in the fibroblasts all peptides were able to 
induce a reduction in surface binding, we also looked into potential MAPK activation by these 
compounds. 
The fibroblasts were stimulated with bradykinin, icatibant or B9430 at a saturating concentration 
of 1 µM for 10 min. The reference agonist, BK, induced ERK1/2 activation (Fig. E-12). On the 
other hand icatibant and B9430 were not capable of significantly inducing any ERK1/2 
activation. 
The determination of phospho-ERK was also performed with the recombinant cell lines. As 
shown by the lack of an effect of BK in untransfected HEK 293 cells, B2R agonist induced 
ERK1/2 phosphorylation is receptor dependent (Fig. E-13).  The reference agonist, BK, induced 
phosphor-ERK activation in B2wtHIGH and B2wtLOW. B9430 showed some inducible phospho-
ERK activation in B2wtHIGH. 
 
 
 
 
 
 
Fig. E-12: Immunoblots for phospho-ERK1/2 and total ERK1/2. 
Foreskin fibroblasts HF-15 were maintained overnight in medium with reduced serum (0.5%). Stimulation 
was performed with 1 µM BK, B9430, or icatibant for 10 min at 37°C. Extraction and detection of total 
ERK1/2 (as loading control) and phospho-ERK1/2 was carried out as described in “Materials and Methods”. 
One representative immunoblot out of two is shown. 
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Fig. E-13: Immunoblots for phospho-ERK1/2 and total ERK1/2. 
HEK 293 cell lines B2wtHIGH and B2wtLOW were maintained overnight in medium with reduced serum (0.5%). 
Stimulation was performed with 1 µM BK, B9430, or icatibant for 10 min at 37°C. Extraction and detection 
of total ERK1/2 (as loading control) and phospho-ERK1/2 was carried out as described in “Materials and 
Methods”. Untransfected HEK 293 cells were also stimulated with 1 µM BK, B9430, or icatibant. One 
representative immunoblot out of at least three is shown. 
 
 
E.1.13 B9430 acts as a surmountable antagonist  
There have been several reports on the angiotensin AT1-receptor concerning surmountable and 
insurmountable antagonism (Panek et al., 1995); (Gradman, 2002); (Fierens et al., 1999) which 
are often identified by concentration-response curves. Taking the angiotensin AT1-receptor as an 
example, agents such as losartan only produce a parallel shift of the dose-response curve to the 
right without reducing the maximal response to angiotensin II. This inhibition can therefore be 
overcome by increasing concentrations of angiotensin II, and hence these agents are described as 
surmountable antagonists. By contrast, other agents such as valsartan or candersartan also depress 
the maximal response to angiotensin II. This inhibition cannot be overcome by increasing 
concentrations of angiotensin II and hence is described as insurmountable antagonism 
(Vanderheyden et al., 2000).  
We performed a concentration-response IP assay on the HF-15 cell line. The fibroblasts were 
incubated for 16 hours with BK, icatibant and B9430. The next day stimulation was performed 
with addition of increasing concentrations (10-11 – 10-6 M) of BK and the EC50 values were 
determined. In this assay B9430 acted as a surmountable antagonist (Fig. E-14). The curve upon 
B9430 incubation is shifted to the right without any depression of the maximal response. BK, on 
the other hand, also depressed the maximal response indicating an insurmountable behavior.  The 
untransfected B2wtHIGH B2wtLOW  
control icatibant BK B9430 control icatibant BK B9430 control icatibant BK B9430 
total ERK1/2 
p-ERK1/2 
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depression of the maximal response was probably due to the sequestration of the receptors that 
was seen in the down-regulation assay of the fibroblasts (Fig. E-7). 
 
 
Fig. E-14: Basal and stimulated IP accumulation in fibroblasts HF-15 upon prolonged stimulation. 
Fibroblasts HF-15 were incubated with 0.5 µCi [3H]inositol in 0.5 ml medium overnight. 10 µM BK (□) , 5 
µM B9430 () and 5 µM icatibant (○) respectively was added to the medium overnight. No pre-incubation 
(■) The next day stimulation was performed with addition of increasing concentrations (10-11 – 10-6 M) of BK 
in the presence of 50 mM LiCl for 30 min at 37°C as described in „Materials and Methods“. Symbols 
represent the mean ± SEM of three experiments performed in duplicates. The EC50 values for the three 
experiments were: non-stimulated (basal) 1.49 ± 0.08 BK; 0.52 ± 0.30 nM; B9430, 14.92 ± 0.22 nM; icatibant 
1.22 ± 0.34 nM. 
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E.2 Alanine-screening of the intracellular loops of the B2 receptor 
We set out to elucidate the participation of the intracellular receptor domains of the B2R in its 
interaction with G proteins, receptor kinases and arrestins through a mutagenesis approach in 
intact cells. These proteins most likely interact with the cytosolic parts of the receptor, i.e. the 
three intracellular loops and the C-terminus. In order to more closely define the receptor 
sequences that are involved in these interactions and the roles they play, we systematically 
mutated all three intracellular loops either as point mutants or in groups of 3-5 amino acids to 
alanines, obtaining 14 mutants (Fig. E-15). Using the Flp-InTM system (Invitrogen) we obtained 
clones of the Flp-InTM T-RexTM cell line that stably expressed the human wild-type B2R and the 
mutants. Expression levels of the wild type receptor in HEK 293 cells were varied as described in 
E.1.1 by using a vector with either the original CMV promoter for higher (B2wtHIGH) expression, 
or the weaker promoter (Pmin) for lower (B2wtLOW) expression. Here it is important to mention 
that even cells with a low expression profile produced copy numbers of B2R that were 
consistently higher than those observed in native cells. All the receptor coding sequences were 
preceded at the N-terminus by a single hemagglutinin (HA)-tag (MGYPYDVPDYAGS). The 
mutants showing strong effects compared to the lower expressed wild type were also generated in 
the low-expression format.   
   
 
 
  
 
 
 
 
Fig. E-15: Mutated sequences in the human bradykinin B2 receptor (Faussner, Wennerberg et al). 
The sequences of the intracellular loops, parts of the transmembrane segments (I –VII) and of the proximal C-
terminus containing the putative helix VIII and the palmitoylated cysteine are depicted. The clusters of amino 
acid residues that have been mutated to alanines are alternating depicted as black circles or white circles with 
a black edge with the respective construct name next to them. The point mutations E66A in the first loop and 
T242A at the end of the third loop are also indicated. The two-dimensional structure of the bradykinin B2 
receptor with the membrane border, the cytosolic extensions of the helical transmembrane domains III and VI 
and the additional cytosolic helix VIII was drawn after the structure published for inactive bovine rhodopsin 
(Palczewski et al., 2000 
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E.2.1 ICL-1 and sequences at the N-terminus of ICL-2 and at the C-terminus of ICL-3 are 
crucial for receptor surface expression. 
Despite the isogenic expression, the maximal receptor numbers (Bmax) of the various constructs 
were quite diverse and several receptor mutants – all ICL-1 mutants and construct 3/5, in 
particular - were significantly lower expressed than the B2wt [11.0 ± 0.7 pmol/mg protein, 
B2wtHIGH] though all were under the control of the same cytomegalovirus (CMV) promoter. We 
already observed that icatibant and B9430 show partial agonism with high B2wt expression. 
Besides the wild type receptor, we generated lower - under the control of the Pmin promoter - 
expressing cell lines for some of the constructs in ICL-3 (Fig. E-16). There were two reasons for 
this. Firstly these constructs 3/2, 3/4 and T242A displayed very high expression levels. Secondly 
the constructs, as will be shown later (Fig. E-19), showed induced IP accumulation also with the 
poor partial agonists (B9430 and icatibant) indicating a semi-active conformation. To test if the 
semi-activity also held true with lower expression, the Pmin constructs were generated. 
Of the constructs with alanine substitutions in the sequence of ICL-1, mutant 1/2 displayed 
particularly low surface receptor binding activity with only 6% of that obtained for B2wtHIGH. 
Exchange of the highly conserved DRY-sequence located at the transition of the cytosolic 
extension of helix 3 and the N-terminus of ICL-2 for three alanines resulted in a binding deficient 
construct (<20 fmol/mg protein). All other constructs with mutations made in ICL-2 were well 
expressed. The mutants made in ICL-3 all revealed high expression levels with the exception of 
mutant 3/5 - positioned at the C-terminus of ICL-3- that displayed only 6% of that obtained for 
B2Rwt. 
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Fig. E-16: Expression levels of constructs (Faussner, Wennerberg et al). 
Maximal binding of [3H]BK to confluent monolayers of HEK 293 cells stably and isogenically expressing the 
indicated constructs was estimated with app. 30 nM [3H]BK on ice as described in „Materials and Methods“. 
The data shown are the mean ± SEM of at least 3 clones. The positions of the amino acids mutated to alanines 
are given in brackets. Expression of constructs under control of the CMV-promoter (open columns); 
constructs under control of the weaker Pmin-promoter (closed columns). 
 
E.2.2 Immunoblot of construct 2/1 
Exchange of the highly conserved DRY-sequence located at the transition of the cytosolic 
extension of helix III and the N-terminus of ICL-2 for three alanines resulted in a binding 
deficient construct. Fig. E-17 shows the immunoblot of HA-tagged mutant 2/1 in comparison 
with those of B2wtHIGH and B2wtLOW (immunoblot generated by Jens Feierler). For both wild type 
cell lines several bands were detected between 50 and 65 kDa with densities that largely reflect 
their relative expression levels and two weaker bands at 42 and 39 kDa. Mutant 2/1 in contrast, 
displayed only strong bands at 42 and 38 kDa and two weaker ones at 36 and 33 kDa. This 
suggests that this receptor mutant is well expressed but might not become processed and 
glycosylated properly, and is therefore unable to reach the plasma membrane. In fact, a fusion 
protein of construct 2/1 with eGFP (enhanced green fluorescent protein) joined to the C-terminus 
demonstrated strong intracellular expression and did also not display any specific surface [3H]BK 
binding activity (not shown). 
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Fig. E-17: Immunoblot of B2Rwt’s and mutant 2/1 (Faussner, Wennerberg et al). 
HEK 293 cells stably expressing high (B2RwtHIGH) or low (B2RwtLOW) amounts of HA-tagged wild type B2R, 
or construct 2/1 were lysed in RIPA buffer as described in “Materials and Methods”. 15 µg of protein were 
separated by SDS-Page and detected by western blot using a monoclonal HA-antibody. Molecular masses of 
standard proteins are indicated on the left side in kDa. Control, mock transfected cells. The blot shown is 
representative of two experiments. Immunoblot generated by Jens Feierler. 
 
E.2.3 Some mutants are in a high affinity state at 37°C. 
Receptor equilibrium binding affinities (Kd) reflect the conformation of the ligand binding site. 
Changes in the affinity may indicate different preferences in coupling or uncoupling of the 
receptor constructs to or from intracellular proteins, such as G proteins, arrestins, or receptor 
kinases, as these interactions might affect also the overall receptor conformation including that of 
the binding site. 
B2wtLOW displayed at 37°C an affinity of 8.05 ± 1.10 nM that was increased by incubation on ice 
to 2.02 ± 0.22 nM (n=5) thus exhibiting an app. 4-fold increase in affinity (Fig. E-18, Tab. 3). 
This was similarly seen for B2wtHIGH with the difference that both affinities were somewhat lower 
(10.42 ±1.56 nM and 2.81± 0.7 nM, respectively). Mutants 1/2 and E66A had a higher affinity 
than B2wtLOW at 37°C (3.21 ± 0.31 nM and 3.77 ± 0.67 nM, respectively) but also showed a shift 
of app. 4-fold to higher affinity when incubated on ice (0.79 ± 0.11 nM and 0.94 ± 0.29 nM, 
respectively) thus upholding their relative higher affinity also at 4°C (Tab. 3). In contrast, mutant 
2/2 in ICL-2 displayed a high affinity at 37°C but exhibited almost no shift to higher affinity on 
ice (2.96 ± 0.74 nM at 37°C vs. 1.8 ± 0.36 nM at 4°C) suggesting that this mutant is also at 37°C 
in a high affinity state. The other mutants in ICL-2 displayed affinity increases at 4°C relative to 
37°C that were similar to those of the B2Rwt’s. 
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With exception of mutant 3/3 all constructs generated in ICL-3 displayed a binding behavior 
distinctly different from the B2wt’s. While the mutations located in the middle of ICL-3 (3/2, 3/4) 
and T242A showed affinities at 37°C that were similar to the ones of the B2wt’s they did not 
respond to incubation at 4°C with an increase in the affinity as strong as seen for the B2wt’s, thus 
displaying a shift of less than 2-fold. The constructs either at the N-terminal (3/1) or at the C-
terminal (3/5) end exhibited a high affinity at 37°C as well as at 4°C (Tab. 3). 
 
 
Fig. E-18: Equilibrium dissociation constants Kd at 37°C and at 4°C (Faussner, Wennerberg et al). 
Binding of [3H]BK (0.01 – 30 nM) to HEK 293 cells stably expressing the indicated constructs was 
determined at 37°C or at 4°C after inhibition of receptor sequestration by pretreatment of the cells with 100 
µM PAO as described in „Material and Methods“. Symbols present the Kd’s as mean ± SEM of at least three 
experiments (also given in table 2). Kd’s at 37°C (open symbols) ; Kd’s at 4°C (closed symbol). Note the 
logarithmic scale of the y-axis. Comparison between Kd values at 37 and 4°C: *P < 0.05; **P < 0.01; ***P < 
0.001; ns, not significant. 
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E.2.4 Basal activity and stimulated accumulation of inositol phosphates (IP) 
Stimulation of the B2Rwt leads to activation of phospholipase C via G protein Gq/11, resulting in 
the release of inositol trisphosphate. In order to determine the effect of the loop mutations on the 
interaction of the receptor with Gq/11, we measured the accumulation of inositolphosphates (IP) in 
the presence of 50 mM LiCl after 30 min with and without stimulation by BK. The fact that some 
of the mutants were not showed no substantial difference in their affinities at 37°C and at 4°C 
suggested that they may be in a permanent higher affinity state, i.e. in a semi-active 
conformation. If so, they might either exhibit a higher basal activity or be activated even by poor 
partial agonists. As mentioned before the pseudopeptides icatibant and B9430 acted as partial 
agonists at high receptor overexpression, but were not able to activate the B2Rwt at all when it 
was expressed at lower levels. Thus, these drugs were well suited for the identification of semi-
active mutants, provided that these constructs were expressed at low levels. 
Activation of most constructs by 1 µM BK induced an 8 -15 fold increase over basal IP 
determined as the amount of IP’s in cells kept on ice (E-19). In our experimental set-up there 
seems to be no direct linear correlation between the induced accumulation of IP’s and the amount 
of expressed receptors as demonstrated by the example of the B2Rwt’s (see table 3) where an 
almost five times higher receptor level (11.0 vs. 2.4 pmol/mg protein) did not result in a 
significantly higher IP response (12.55 ± 1.00 nM vs. 12.11 ± 1.22 nM). 
None of the loop mutations displayed an increased constitutive, i.e. e. agonist-independent, 
activation of the receptor, as their basal activity was not significantly higher than that observed 
for the B2Rwt’s. 
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Fig. E-19: Basal and stimulated accumulation of total inositol phosphates (Faussner, Wennerberg et al). 
Cells in 12-well plates were incubated overnight with 0.5 µCi [3H]inositol in 0.5 ml culture medium. The 
monolayers were washed briefly and incubated with incubation buffer containing 50 mM LiCl ± 1 µM of the 
indicated peptides for 60 min on ice. IP accumulation (basal and stimulated) was started by placing the plates 
in a water bath at 37°C. The stimulation was stopped after 30 min and total inositol phosphates were 
determined as described in „Materials and Methods“. Each column represents the mean ± SEM of at least 
three independent experiments done in duplicates, given as fold over the IP content of identically treated 
control cells that had remained in the same buffer on ice. Basal (black columns), BK (open columns), B9430 
(hatched columns), icatibant (grey columns). Stars indicate constructs lower expressed under the control of 
the Pmin-promoter (mutant 3/2, 4.0 ± 0.2 pmol/mg protein; mutant 3/4, 6.0 ± 0.4 pmol/mg protein; mutant 
T242A, 3.8 ± 0.5 pmol/mg protein). Comparison between basal and stimulated IP accumulation: *P < 0.05; 
**P < 0.01; ***P < 0.001. 
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E.2.5 EC50 of IP accumulation.  
There was no significant difference in the EC50 obtained with the two differently expressing 
B2Rwt’s, demonstrating that at these levels the efficiency/potency is independent of the number 
of receptors (Fig. E-20, Tab. 3). All mutants made in ICL-1 were almost as efficient (1/1) or even 
more significance (1/2, E66A) than the B2Rwt’s in stimulating IP accumulation. Of the constructs 
generated in ICL-2, 2/2 displayed a slightly increased (approx. 4-fold) and 2/3 and 2/4 a strongly 
increased EC50 (approx. 15-fold) when compared to the B2Rwt’s. Only mutant 2/5 exhibited a 
comparable EC50. All cluster mutations but not point mutation T242A of ICL-3 – (due to its poor 
activity it was not possible to determine an EC50-value for mutant 3/5) - exhibited a distinctly 
reduced efficiency. This reduction was more pronounced for 3/1 – 3/3 (app. 4-fold) located at the 
N-terminus and in the middle of the loop, and only minor (app. 2-fold) for 3/4.  
 
 
Fig. E-20: EC50 values of IP accumulation (Faussner, Wennerberg et al). 
Cells were treated and incubated with increasing concentrations of BK (from 10-12 to 10-5 M) for 30 min at 
37°C and the generation of total IP was determined as described in „Materials and Methods“. The EC50 is 
given as mean ± SEM of the number of experiments indicated in table 2. Note the logarithmic scale of the y-
axis. Comparison with EC50 values of both high and low B2Rwt: ***P < 0.001. 
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E.2.6 Internalization 
After stimulation most GPCRs including the B2 receptor are sequestered to compartments within 
the cell. Recent publications indicated that the intracellular loops of GPCRs might not only be 
involved in the interaction with their cognate G proteins but may also serve - together with 
(phosphorylated) serine/threonine residues in the C-terminal tail- as contact sites for arrestins and 
G protein-coupled receptor kinases thus playing also a part in the internalization (Marion et al., 
2006);  (Huttenrauch et al., 2002). In addition, diminished/increased ability to interact with the 
cognate G protein(s) or an altered capability of activating them might also affect this process. We 
therefore also looked at the [3H]BK internalization properties of the various constructs. Having 
demonstrated that internalization decreases when too many receptors are occupied in 
overexpressing cells (Faussner et al., 1999) we took care to use non-saturating concentrations of 
less than 2 nM [3H]BK. Under these conditions, where the internalization machinery was not 
expected to be limiting, none of the constructs exhibited internalization that was distinctly slower 
than that observed for the B2wtHIGH (Fig. E-21). This suggests that the amino acid residues 
involved are not of pivotal significance for the internalization. It cannot, however, be excluded 
that the affinities for receptor kinases and arrestins have changed for the mutants as compared to 
the B2wt without affecting the internalization under our conditions. Furthermore, due to its lack 
of surface binding activity no results could be obtained for the mutant 2/1, i.e. participation of the 
highly conserved DRY sequence in the internalization process cannot be excluded by our data. 
 
        
Fig. E-21: Internalization of [3H]BK (Faussner, Wennerberg et al). 
Cells expressing the B2wtHIGH or the indicated receptor constructs were preincubated with 2 nM [3H]BK for 
90 min on ice. Internalization was initiated by warming the plates to 37°C in a water bath. At the indicated 
time points the internalization was stopped and surface-bound and internalized [3H]BK were determined by 
acetic acid treatment as described in „Materials and Methods“. Internalization is given as a percentage of total 
bound [3H]BK. Data points represent the mean ± SEM of at least three experiments performed in duplicate or 
triplicate. 
 RESULTS 68
E.2.7 Summary of data for the loop mutants 
Tab. 3: [3H]Binding data, basal and BK-induced IP accumulation (Faussner, Wennerberg et al). 
 
                          [3H]BK Binding                Inositol Phosphate Accumulation   
         –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Receptor-    Bmaxa             Kd(PAO/37°C)    Kd (PAO/4°C)   Kd-ratio        basalb           maximal effectb       EC50c         
construct        [pmol/mg prot.]       [nM]                [nM]         37°C/4°C                                                       [nM]    
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
B2wtHIGH    11.0±0.7 10.42±1.56(4) 2.81±0.7 3.7 2.02±0.13(8) 12.55±1.00   0.79±0.34(4) 
B2wtLOW   2.4±0.3   8.05±1.10(5) 2.02±0.22 4.0 1.69±0.09(4) 12.11±1.22   0.67±0.22(3) 
1/1(CLHK)   2.3±0.3 10.18±0.21(3) 2.25±0.37 4.5 1.76±0.17(6) 14.18±1.44   1.04±0.21(5) 
1/2(SSCT)   0.9±0.1   3.21±0.31(3) 0.79±0.11 4.1 1.61±0.05(4)   5.58±0.09   0.43±0.08(6) 
E66A   0.7±0.4   3.77±0.67(3) 0.94±0.29 4.0 1.81±0.11(6)   6.77±1.25   0.37±0.07(3) 
 
2/1(DRY)     < 0.02         n.a.       n.a n.a.       n.a.                      n.a.         n.a. 
2/2(LALV)   5.3±0.2   2.96±0.74(3) 1.80±0.36 1.6 1.88±0.13(5) 10.19±1.50   2.96±0.28(4) 
2/3(KTMSM)   9.5±0.7   9.22±1.50(3) 2.80±0.49 3.3 1.49±0.07(3)   8.17±0.72 11.66±1.94(6) 
2/4(GRMR) 10.2±0.3 14.19±1.36(3) 3.64±0.17 3.9 1.40±0.11(6)  9.90 ± 2.20 11.56±3.02(5) 
2/5(GVR) 10.3±0.6 12.99±0.78(4) 4.43±0.57 2.9 1.59±0.14(8) 14.46±1.10   1.33±0.22(5) 
 
3/1(MQVLR)     5.0±0.6   3.45±0.53(5) 1.87±0.45 1.8 1.72±0.18(5)   6.91±1.22   3.17±0.45(3) 
3/2(NNEMQ) 11.0±1.3   9.54±0.90(3) 5.37±1.38 1.8 1.55±0.12(5)   7.37±0.86   3.12±0.42(5) 
3/3(KFK)   4.3±0.7   7.93±1.27(3) 2.18±0.37 3.6 2.05±0.17(4) 10.09±1.14   3.78±0.64(4) 
3/4(EIQ) 13.7±0.8   8.52±1.74(4) 5.24±1.07 1.6 1.87±0.33(3) 10.53±3.25   1.49±0.18(4) 
3/5(TERR)   0.7±0.0   1.63±0.50(3) 0.86±0.29 1.9 1.54±0.16(5)   2.07±0.38          n.a. 
T242A 12.7±0.6   6.70±0.93(3) 3.38±0.60 2.0 1.93±0.07(3) 11.37±0.72   0.97±0.27(4) 
 
a estimated from at least 3 different clones in 24-wells after incubation with 200 µl 30 nM [3H] BK on ice. 
b Total IP accumulation after 30 min incubation in buffer with inhibitors and 50 mM LiCl at 37°C with (maximal 
effect) and without (basal) 1 µM BK, expressed as fold increase of initial total IP production (t= 0 min). The results 
represent the mean ± SEM of the number of experiments (given in brackets) performed in triplicates. 
c Calculated from incubations in duplicates with 10-12 to 10-5 M BK for 30 min at 37°C in the presence of 50 mM 
LiCl. Results are the mean ± SEM of independent experiments (number indicated in brackets) 
n.a. not applicable 
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E.3 R3.50 in the DRY motif and E6.30 in the TERR motif as key players for 
the activation and trafficking of the human bradykinin B2 receptor 
 
The highly conserved DRY motif is located at the C-terminal end of the 3rd transmembrane helix 
of family A GPCRs. It is known to play a crucial role in regulating GPCR conformational states. 
The crystal structure of the ground state of rhodopsin indicates that the side chain of arginine 3.50 
in the DRY motif forms salt bridges with the preceding aspartate side chain and with the side 
chain of glutamate at position 6.30 on helix 6, suggesting that disruption of these salt bridges may 
be a key step towards receptor activation. This interaction between R3.50 and E6.30 is also 
known as the “ionic lock”. Positions R3.50 and E6.30 are depicted in Fig. E-22. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. E-22: Schematic two-dimensional representation of a family A GPCR (Wennerberg et al. submitted).  
Highly conserved residues are shown as white circles with the one letter code for the amino acid in black. The 
two residues involved in the formation of the “ionic lock” are depicted in black circles with white letters.  
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We set out to investigate the role of these two conserved amino acids in the human bradykinin B2 
receptor by mutating them to alanines (termed mutants R3.50A and E6.30A). To determine the 
influence of receptor densities, the two mutants were expressed under the CMV promoter and the 
weaker Pmin promoter in HEK 293 cells. To determine whether both these two mutants were in 
semi-active conformations, their responses to the poor partial agonists, icatibant, and B9430, 
were examined.  
 
E.3.1 Expression 
In the cell line R3.50AHIGH, with expression under the control of the strong CMV promoter, the 
yield was nearly 4 pmol receptor/mg of total membrane protein. In the cell line R3.50ALOW, 
under the control of the Pmin promoter, the level reached 1.5 pmol/mg protein (Fig. E-23). For 
E6.30AHIGH the expression was slightly lower than for R3.50AHIGH at 3.5 pmol/mg protein. 
E238ALOW expression reached approximately 1.3 pmol/mg protein. A saturating concentration of 
approximately 30 nM [3H]BK was used for the experiments. 
 
Fig. E-23: Bradykinin B2 receptor expression levels in R3.50A and E6.30A in comparison to B2wt 
(Wennerberg et al, submitted). 
Maximal [3H]BK binding Bmax of HEK 293 cells isogenically and stably expressing high or low amounts of 
R3.50A and E6.30A was determined with approximately 30 nM [3H]BK on ice as described in „Materials and 
Methods“. The data shown is the mean ± SEM of at least four binding experiments.  The receptor expression 
in R3.50AHIGH/E6.30AHIGH was under control of the CMV-promoter, whereas in R3.50ALOW/E6.30ALOW 
expression was driven by the weaker Pmin promoter.  
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E.3.2 E6.30A showed no affinity shift between 37°C and 4°C. 
Receptor equilibrium binding affinities (Kd) reflect the conformation of the extracellularly 
located ligand binding site. Coupling and uncoupling of intracellular proteins to and from the 
receptor also affect the conformation of the receptor, including that of the binding site (Enquist et 
al., 2007). Differences in the affinities of the constructs may therefore indicate a change in the 
receptor coupling preferences. Alternatively, they could be the consequence of a change of 
overall receptor conformation induced by the mutation. Representative equilibrium binding 
curves of B2wtLOW at 4°C (after pre-incubation at 37°C) and at 37°C are shown in Fig. E-24, A. 
The average Kd´s obtained from at least 4 independent experiments for B2wtLOW were 2.02 ± 0.22 
nM at 4°C and 8.05 ± 1.10 nM at 37°C, and 2.81 ± 0.7 nM at 4°C and 10.42 ± 1.56 nM at 37°C 
for B2wtHIGH (see Tab. 4), demonstrating that the B2R has a lower affinity at 37°C than at 4°C. 
Corresponding representative equilibrium binding curves at 4°C and at 37°C of R3.50ALOW and 
E6.30ALOW are displayed in Fig. E-24, B and Fig. E-24, C, respectively. These curves and the 
mean Kd’s calculated from several experiments (Tab. 4) reveal that at 4°C the B2wt and the 
mutant constructs have equal affinities. At 37°C, in contrast, the affinities of R3.50A and of 
E6.30A are significantly higher than that observed for the less well expressed B2wtLOW. Mutant 
E6.30ALOW even displayed at 37°C an affinity that was almost identical to that determined at 
4°C. The fact that both mutants remain in a higher affinity state at 37°C after activation suggests, 
according to the extended ternary model (Samama et al., 1993), a permanent constitutive or semi-
active receptor conformation. 
 
Fig. E-24: Saturation binding curves at 4°C and at 37°C (Wennerberg et al, submitted). 
Binding of [3H]BK to HEK 293 cells stably expressing the indicated constructs was determined at 4°C (after 
pre-incubation at 37°C) and at 37°C with inhibition of receptor sequestration by pretreatment of the cells with 
100 µM PAO, as described in „Experimental“. Three representative binding curves are shown: (A) B2wtLOW; 
(B) construct R3.50ALOW; (C) construct E6.30ALOW. The Kd values of all constructs as mean ± SEM of at 
least three experiments are given in Tab. 4. 
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E.3.3 Accumulation of inositoltrisphosphates 
Next the ability of the point mutants to activate the G protein was measured. As already seen and 
also shown here, high and low expressed B2Rwt cells responded to a challenge with 1 µM BK 
with a similar strong inositolphosphate accumulation in the presence of 50 mM LiCl (Fig. E-25). 
In contrast, neither the high nor the lower expressed mutant R3.50A was able to induce 
phosphatidylinositol hydrolysis after binding of BK, indicating that R3.50 is crucial for a 
productive interaction of B2R with G protein Gq/11. Both cell lines expressing construct E6.30A 
responded to BK with strong accumulation of IPs, albeit the poorer expressing cell line gave a 
clearly weaker response. 
The fact that E6.30A displayed a high affinity for BK at 37°C (Fig. E-24, C), indicated that this 
mutant might be in a permanent high affinity state, which usually suggests a constitutive or semi-
active conformation. However, as the E6.30A construct displayed no increased basal PI 
hydrolysis activity (Fig. E-25, table 4) it was apparently not in a constitutively active state with 
regard to G protein activation.  
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Fig. E-25: Basal and stimulated accumulation of total inositol phosphates (Wennerberg et al, submitted). 
HEK 293 cell lines R3.50A and E6.30A together with B2wt were incubated overnight in 12-well plates with 
0.5 µCi [3H]inositol in 0.5 ml medium. Stimulation was performed in the presence of 50 mM LiCl and 1 µM 
BK, B9430 and icatibant for 30 min at 37°C as described in „Materials and Methods“. Each value represents 
the mean ± SEM of at least three independent experiments done in triplicates, given as fold over the IP 
content of non-stimulated but other identically treated control cells that had remained on ice. Basal (black 
columns), BK (open columns), B9430 (hatched columns), icatibant (grey columns).  ***P < 0.001. 
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As shown before mutant receptors with semi-active conformations can be identified by their 
stronger response to partial agonists than the wild type. In both cell lines expressing construct 
E6.30A, B9430 and icatibant behaved as full agonists inducing an IP release comparable to that 
obtained with BK (Fig. E-25). This strongly indicates that mutation of E6.30 to alanine induces a 
semi-active receptor conformation. Neither low nor high expressed mutant R3.50A gave an IP 
response to a challenge with the antagonists. 
 
E.3.4 The antagonist [3H]NPC17331 promotes internalization of R3.50A and E6.30A. 
Due to the decisive role of R3.50 in the activation of Gq/11 it was not possible to use the poor 
partial agonists B9430 and icatibant as phospholipase C activation to identify a potential semi-
active state of this mutant. However, the availability of a structurally related tritiated compound, 
[3H]NPC17331, also usually considered an antagonist, allowed us to test for constitutive or semi-
active receptor states by comparing the internalization properties of B2Rwt to those of the 
mutants. 
Both constructs R3.50A and E6.30 internalized upon application of [3H]BK as efficiently as 
B2Rwt, displaying approximately 80% internalization after 10 min (Fig. E-26) and thereby 
demonstrating that (i) these mutations do not negatively affect the internalization process under 
the applied conditions, and (ii) this process is obviously independent of G protein stimulation 
since R3.50A is G protein activation incompetent (Fig. E-25). 
B2Rwt did not internalize with [3H]NPC17331 (< 5% after 10 min at 37°C). In contrast, for 
mutant R3.50A approximately 25% of specifically bound [3H]NPC17331 was detected after 10 
min in acetic acid resistant compartments (Fig. E-26). An even stronger effect was observed for 
E6.30A, that displayed approximately 65% internalization of bound [3H]NPC17331. The results 
indicate semi-active or constitutively active receptor conformations for mutants E6.30A and 
R3.50A with regard to receptor internalization. A question arising was whether NPC17331 
behaves as a partial agonist (similar to B9430 and icatibant) capable to induce ligand-mediated 
receptor internalization in these mutants (indication of a semi-active conformation) or whether it 
is a neutral antagonist that got internalized bound to constitutively internalizing receptor mutants 
(indication of a constitutively active conformation).  
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Fig. E-26: Internalization of [3H]BK and [3H]NPC17331 (Wennerberg et al, submitted). 
HEK 293 cells stably expressing B2wtHIGH, R3.50AHIGH and E6.30AHIGH were preincubated with 2 nM [3H]BK 
for 90 min on ice. Internalization was started by warming the plates up to 37°C in a water bath. After 10 min 
surface-bound and internalized [3H]BK were determined by acetic acid treatment as described in „Materials 
and Methods“. Internalization is given as percentage of total bound [3H]BK (surface plus internalized 
[3H]BK). Data points represent the mean ± SEM of at least three experiments performed in duplicates or 
triplicates. [3H]BK, 4°C (open columns); [3H]BK, 37°C (black columns); [3H]NPC17331, 4°C (grey 
columns); [3H]NPC17331, 37°C (hatched columns). 
 
E.3.5 R3.50A and E6.30A are both constitutively internalized 
With the biotinylation protection assay (BPA) it was possible to differentiate between ligand- 
dependent and -independent receptor internalization. As shown previously, B2RwtLOW displayed 
strong internalization upon BK stimulation (Fig. E-26). In the absence of BK or in the presence 
of B9430 and icatibant no intracellular receptors were detected after 1 hour, hence B2Rwt did not 
display any ligand-independent or “antagonist”-inducible internalization (Fig. E-27). Also, 
mutants R3.50A and E6.30 responded to BK with clear receptor internalization. But even in the 
absence of BK a strong signal was detected, indicating ligand-independent receptor 
internalization (Fig. E-27). This demonstrates that both mutants are in a constitutively active 
conformation where the interaction with the cellular internalization machinery is concerned. The 
compounds B9430 and icatibant slightly enhanced this constitutive internalization, with E6.30A 
reaching an internalization level similar to the one induced by BK.  
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Fig. E-27: Receptor endocytosis as determined by BPA (Wennerberg et al, submitted). 
HEK 293 cells stably expressing B2wtLOW, R3.50ALOW and E6.30ALOW having a hemagglutinin tag at the N-
terminus were labeled at 4ºC with a biotin reagent containing a reducible linker. The cells were then either 
stripped directly or incubated in the absence (NS = nonstimulated) or presence of 10 µM BK, 5 µM B9430 or 
5 µM icatibant for 1 hour at 37 ºC and then stripped. The receptors were then treated with Anti-HA agarose 
beads and visualized by Vectastin followed by development with ECL reagents as described for biotinylation 
protection assay under „Materials and Methods“. The blots shown are representative of three experiments. 
 
 
E.3.6 Localization of receptor constructs with epifluorescence microscopy 
For the determination of the effects of the constitutive internalization on the cellular distribution 
of the receptors, we visualized the localization of receptor constructs by epifluorescence 
microscopy using eYFP (enhanced yellow fluorescent protein) genetically fused to their C-
termini. In order to avoid any receptor internalization caused by BK present in the medium, we 
used the tetracycline-inducible Flp-In expression system (Invitrogen) and exchanged the normal 
cell culture medium for serum-free OPTI-MEM before inducing receptor-eYFP expression 
(under Pmin promoter control) for 16 h. B2RwteYFP was localized exclusively at the cell 
membrane, and responded only to BK, but not to B9430 or icatibant, with clear translocation into 
intracellular vesicles (Fig. E-28). In contrast, both mutants, in particular E6.30A, displayed 
fluorescence at the cell membrane as well as in vesicles of various sizes throughout the cytosol in 
the absence of BK; most likely as a result of constitutive receptor internalization. Moreover, both 
constructs responded not only to BK, but also to B9340 and icatibant with additional receptor 
translocation into the cell, thus confirming their semi-active conformation state. 
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B2wt-eYFP                   R3.50A-eYFP            E6.30A-eYFP  
            
         
          
         
                                                                                                                  
         
 
         
Fig. E-28: Localization of wild-type and mutant receptor-eYFP fusion proteins by epifluorescence microscopy 
(Wennerberg et al, submitted).  
Live HEK 293 cells stably expressing constructs of eYFP fused to the C-terminus of B2wt, R3.50A or E6.30A 
under the control of the weak Pmin promoter were incubated in the absence or presence of 1 µM BK, B9430, 
or icatibant for 30 - 60 min at 37°C. Images were taken with a epifluorescent microscope focusing at a layer 
halfway through most of the cells. 
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E.3.7 Down-regulation 
The effect of long-term incubation with BK, icatibant and B9430 was further investigated with a 
down-regulation assay (Fig. E-29). At the times indicated, all bound and free unlabeled BK was 
removed with an acetic acid solution and the remaining specific surface binding was determined 
with 2 nM [3H]BK at 4°C. Once again, differences were observed concerning the same cell-line 
with different cell densities. In R3.50AHIGH both BK and B9430 induced a reduction in surface 
binding. The receptor number/binding capacity was reduced by 60 % after two hours with B9430 
(Fig. E-29). With BK a 50% reduction was observed after two hours. Upon stimulation with 
icatibant much less receptor sequestration was seen, a maximum of 20 % after 8 hours. For 
R3.50ALOW the same order of binding reduction was observed after stimulation (B9430 > BK > 
Icatibant), but the sequestration of cell surface receptors was more rapid then with R3.50AHIGH. 
Upon stimulation for half an hour with B9430 80 % of R3.50ALOW receptors were sequestered, 
while during the same time period 75 % sequestration was seen upon BK stimulation (Fig. E-30). 
After the immediate strong reduction of cell surface receptors a plateau was reached and no 
further increase in sequestration was detected. E6.30A displayed in some way a different pattern 
than R3.50A concerning reduction of cell surface receptors. In contrast to R3.50AHIGH, icatibant 
induced receptor sequestration of E6.30AHIGH (Fig. E-29). After 8 hours of icatibant stimulation 
about 60 % sequestration was detected, which was the same level as for BK. B9430 induced 
approximately 90 % sequestration after 8 hours. Once again the same cell line with lower 
expression yielded more rapid receptor sequestration upon stimulation with all three compounds 
(Fig. E-30).  
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Fig. E-29: Effect of prolonged stimulation with BK, B9430 and icatibant on surface binding.  
HEK 293 cells isogenically and stably expressing high amounts of  R3.50A and E6.30A were incubated with 
10 µM BK or 5 µM B9430 and icatibant in medium at 37°C as described in “Materials and methods”. At the 
times indicated, all free and bound (pseudo)peptide was removed with an acetic acid/NaCl solution. 
Thereafter, the remaining specific surface binding was determined with 2 nM [3H]BK at 4°C. Symbols 
represent the mean ± SEM for at least three experiments performed in duplicate. 
 
Fig. E-30: Effect of prolonged stimulation with BK, B9430 and icatibant on surface binding. 
HEK 293 cells isogenically and stably expressing low amounts of R3.50A and E6.30A were incubated with 
10 µM BK or 5 µM B9430 and icatibant in medium at 37°C as described in “Materials and methods”. At the 
times indicated, all free and bound (pseudo)peptides were removed with an acetic acid/NaCl solution. 
Thereafter, the remaining specific surface binding was determined with 2 nM [3H]BK at 4°C. Symbols 
represent the mean ± SEM for at least three experiments performed in duplicate. 
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E.3.8 R3.50A shows higher basal phosphorylation than wild type 
In both HEK 293 cells and human fibroblasts, B2wt displays distinct phosphorylation even in the 
absence of a stimulus (Blaukat et al., 2001); (Kalatskaya et al., 2004). Most GPCRs respond to 
activation of the receptor by an agonist with internalization/sequestration of the receptor to 
intracellular compartments. As was demonstrated (Fig. E-26) the non-signaling mutant R3.50A 
internalized [3H]BK as rapidly as the B2wt. This clearly demonstrates that the internalization 
process is largely independent of the activation of the G protein. Our phosphorylation 
experiments (performed by Dr. Irina Kalatskaya) revealed that R3.50A exhibits a higher basal 
phosphorylation compared to B2wt (Fig. E-31). However, when challenged with BK, the 
phosphorylation level of R3.50A increased further.  
 
 
 
 
 
 
 
 
 
 
 
Fig. E-31: Agonist-induced phosphorylation of B2wt and R3.50A (Wennerberg et al, submitted). 
Upper panel, HEK 293 cells expressing B2wtHIGH or R3.50AHIGH were labeled for 10 h with 
[32P]orthophosphate before stimulation with 1 µM BK for 5 min. Cells were lysed, and receptor proteins were 
solubilized, immunoprecipitated, and visualized by autoradiography as described in the „Materials and 
Methods“ section. Molecular size markers are indicated to the left. As a control, mock-transfected HEK 293 
cells were used. Lower panel, protein phosphorylation, given as optical densities of the bands in the area 
between 50 and 85 kDa, are presented as means ± S.D. from three independent experiments; unstimulated 
B2wt was set as 100%.  
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E.3.9 MAPK kinases ERK1/2 
It was already demonstrated that BK stimulation of B2wt induces activation of ERK1/2 
phosphorylation (Fig. E-13). Here we compare the effects of the mutations R3.50A and E6.30A 
on the phosphorylation of ERK1/2. In contrast to the wild type receptor, mutants R3.50A and 
E6.30 responded to both the “antagonists” with significant ERK1/2 phosphorylation (Fig. E-32). 
These results confirm semi-active states for both receptor mutants and further demonstrate that 
ERK1/2 phosphorylation is independent of G protein activation as it was also observed for 
mutant R3.50A. 
 
 
 
 
 
 
 
 
Fig. E-32: Immunoblots for phospho-ERK1/2 and total ERK1/2 (Wennerberg et al, submitted). 
HEK293 cell lines R3.50ALOW and E6.30ALOW were maintained overnight in medium with reduced serum 
(0.5%). Stimulation was performed with 1 µM BK, B9430, or icatibant for 10 min at 37°C. Extraction and 
detection of total ERK1/2 (as loading control) and phospho-ERK1/2 was carried out as described in 
“Materials and Methods”. One representative experiments out of at least three are shown. 
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E.3.10 Summary of results of R3.50A and E6.30A 
Table 4: [3H]Binding data and basal and BK-induced IP accumulation of all receptor constructs (Wennerberg 
et al, submitted). 
 
   [3H]BK Binding    Inositol-Phosphate Accumulation 
Receptor-       Bmaxa        Kd (PAO/4°C)  Kd(PAO/37°C) Kd-ratio      basalb        maximal effectb     EC50c 
construct       [fmol/mg prot.]   [nM]                  [nM]     37°C/4°C                                            [nM] 
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
B2wtHIGH     11.0±0.7 2.81±0.7(4)   10.42±1.56*         2.02±0.13(8) 12.55±1.00   0.79±0.34(4) 
B2wtLOW    2.4±0.3 2.02±0.22(5)   8.05±1.10**       1.69±0.09(4) 12.11±1.22   0.67±0.22(3) 
R3.50AHIGH    3.87±0.64 2.09±0.17(6)   5.53±0.64***       1.30±0.26(3) 2.12±0.22         n.a 
R3.50ALOW    1.42±0.25 2.15±0.21(6)   5.15±0.30***       1.43±0.16(3) 1.55±0.10            n.a. 
E6.30AHIGH    3.44±0.61 1.10±0.19(5)   2.17±0.39 n.s.      2.09±0.02(3) 13.79±1.66   2.65±0.73(4) 
E6.30ALOW    1.28±0.18 1.19±0.25(6)   1.32±0.14 n.s.      1.60±0.09(4) 4.14±0.45   0.65±0.18(4) 
 
a Estimated from at least three different clones in 24-wells after incubation with 200 µl of 30 nM [3H]BK on ice. 
b Total IP accumulation after 30 min of incubation in buffer with inhibitors and 50 mM LiCl at 37°C with (maximal effect) and without (basal) 1 
µM BK, expressed as the fold increase of initial total IP production (t = 0 min). The results represent the mean ± SEM of the number of 
experiments (given in parentheses) performed in triplicate. 
c Calculated from incubations in duplicate with 10-12-10-5 M BK for 30 min at 37°C in the presence of 50 mM LiCl. Results are the mean ± SEM 
of independent experiments (number indicated in parentheses) 
Comparison between Kd values at 37 and 4 °C: *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant 
n.a. not applicable 
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E.3.11 Influence of amino acid used for substitution of R3.50  
It is known that both the acidic (Asp, position D3.49) and the basic (Arg R3.50) residues of the 
DRY motif are important for isomerization of receptors between the inactive and activated 
conformations (Flanagan, 2005). We therefore determined the accumulation of IPs when the two 
charged amino acids where swapped using the double mutant D3.49R3.50/R3.49D3.50 (named 
DR3.49/3.50RD). The double mutant DR3.49/3.50RD did not induce any IP accumulation (Fig. 
E-33). Furthermore, the basic arginine R3.50 was mutated to aspartic acid and to isoleucine, 
giving point mutants R3.50D, R3.50I, respectively. The introduction of isoleucine, as that with 
alanine, result in an aliphatic substitution. In contrast, with point mutation R3.50D, the basic 
charged amino acid was replaced with an acidic charged amino acid.  
R3.50I gave approximately a 4-fold increase in IP accumulation upon BK stimulation (Fig. E-
33). When the arginine was replaced with the acidic aspartic acid, no IP accumulation was 
observed.  
0 1 2 3 4 5 6 7 8 9 10 11
DR3.49/3.50RD
R3.50I
R3.50D
R3.50A
basal
BK
B9430
Icatibant
Inositolphosphate Accumulation
[fold basal (t=0 min)]
 
Fig. E-33: Basal and stimulated accumulation of total inositol phosphates. 
HEK 293 cell lines expressing high levels of R3.50 mutants were incubated overnight in 12-well plates with 
0.5 µCi [3H]inositol in 0.5 ml medium. Stimulation was performed in the presence of 50 mM LiCl and 1 µM 
BK, B9430 and icatibant for 30 min at 37°C as described in „Materials and Methods“. Each value represents 
the mean ± SEM of at least three independent experiments done in triplicates, given as fold over the IP 
content of non-stimulated but otherwise identically treated control cells that had remained on ice.  
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F DISCUSSION 
F.1 Functional selectivity of B9430 and icatibant concerning PLC activation 
receptor down-regulation, and ERK1/2 activation depends on human 
bradykinin B2 receptor density and cell type 
 
The two pseudopeptides icatibant and B9430 have a sequence that is related to that of the agonist 
bradykinin but they contain substitutions with artificial amino acids that renders them structurally 
constrained. Both are nominally used as antagonists. In the present study we demonstrate that 
both compounds could act as partial agonists. The agonistic/antagonistic behavior of these two 
compounds depends on the expression level of B2R, the cell type and especially on the signal 
processes under consideration.  
 
F.1.1 B9430 and icatibant act as poor partial agonists in HEK 293 cells expressing high 
amounts of recombinant B2R 
There was almost no difference in the maximal response to bradykinin between the low and the 
high expressing recombinant cell line concerning inositolphosphate- and calcium release. 
Although no difference in the maximal response to BK was detected, there was a difference in the 
turn off of the signal generated by the pseudopeptides icatibant and B9430. While in the lower 
expressing cell line the signal elicited by the pseudopeptides apparently could be kept in check by 
the cellular machinery, this did not function anymore with the high expressing cell line, 
suggesting that the inactivation machinery can be saturated. This indicated that in HEK 293 cells 
expressing recombinant B2R both icatibant and B9430 are poor partial agonists, but only with 
very high B2R numbers can they overcome the turn-off mechanisms and generate a signal. These 
results demonstrate that for the classification of a compound as an antagonist, agonist or inverse 
agonist the cellular context is important and – see below - also the signal transduction pathways 
that have been investigated. 
 
F.1.2 B9430 induced an affinity shift in B2wtLOW 
The effect of the pseudopeptides on receptor surface binding showed another scenario. Here, the 
lower the expression the stronger the effect of the compounds, in particular of B9430. 
 DISCUSSION 84
There was almost no reduction of binding activity after prolonged stimulation with the 
(pseudo)peptides in B2wtHIGH, which might indicate that the sequestration apparatus is 
overwhelmed by the high number of activated receptors. It has still to be determined whether this 
happens on the level of the phosphorylation by GRKs, the arrestins or the vesicle formation. The 
fact that with lower expression the “antagonists” begin to show effects regarding the receptor 
surface binding suggests that there are differences in the inactivation mechanisms between those 
concerning the release of IP3 and calcium and those regarding receptor surface binding. The focus 
seems to be on protection of the cell against overstimulation, therefore the signaling is blocked 
efficiently in lower expressing cells, but reduction of receptor binding can be induced even by 
poor partial agonists.  
 
Even though a reduction of surface binding of B2wtLOW was observed in the down-regulation 
assay upon incubation with B9430, no localization of intracellular receptors could be detected 
upon stimulation as shown using three other methods (immunoblot studies to examine for 
degradation of total levels of B2R protein, receptor localization with epifluorescence microscopy 
and biotinylation protection assay). These results are in contrast to the sequestration induced by 
icatibant observed for a rabbit B2R-GFP construct (Houle et al., 2000). This might be due to 
species differences although the similarity between rabbit und human B2R is almost 80%. 
 
One explanation for reduction of binding could be an affinity shift induced by B9430, that would 
not have been detected in the down regulation assay because only one concentration of [3H]BK 
around the Kd of the B2Rwt is used (2nM). We tested this hypothesis by generation of 
equilibrium binding curves with increasing concentrations of [3H]BK followed by scatchard plot 
analysis. Indeed, long-term stimulation of B2wtLOW with B9430 resulted in a major affinity shift 
as compared to non-treated cells. There could be several reasons for this affinity shift upon long-
term treatment with B9430. One is a slow dissociation of unlabeled ligand from the receptor or its 
insufficient removal after the pretreatment. This would result in competition with [3H]BK and 
therefore in reduced binding, thus simulating an affinity shift of the B2R. This possibility can, 
however, be excluded because the same effect should have then been observed also for the 
B2wtHIGH, which was not the case. It is, therefore, more likely that the pretreatment with B9430 
affects the receptor conformation either directly, or indirectly via changing its interaction with 
intracellular proteins. 
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F.2 Alanine-screening of the intracellular loops of the B2 receptor 
 
The purpose of this part of the thesis was to identify which sequences of the B2 receptor that play 
a major role in signal transduction and in receptor sequestration, i.e. are involved in the 
interaction with the G protein, the receptor kinases and the arrestins. Moreover, to obtain 
knowledge about which sites are involved in binding and which are involved in signaling. In 
order to avoid any bias by focusing only on highly conserved residues, we systematically mutated 
all three intracellular loops (ICLs). To reduce the number of constructs we started with the 
generation of 12 cluster mutations (3 - 5 amino acids) and two point mutants. In total, only one 
mutant (construct 2/1) out of the 14 constructs displayed no binding activity at all, several others 
exhibited low expression though signaling could be measured, and only one mutant (construct 
3/5) displayed no signaling at all, despite detectable ligand binding.  
All mutations in ICL-1 resulted in a strong reduction in expression levels without affecting 
either receptor signaling or sequestration. These results were in agreement with reports on the rat 
B2R (Yu et al., 2005) as well as rhodopsin (Yeagle et al., 1997) indicating that ICL-1 forms a 
tight bend, the disturbance of which strongly affects the receptor expression level. Thus, ICL-1 is 
important for the maintenance of the overall receptor structure and stability, but is apparently of 
no functional importance otherwise. 
Our results indicated that both the intracellular loops ICL-2 and ICL-3 are strongly involved in 
the interaction with Gq/11, but in different ways. Mutations in the ICL-2 resulted in a strong 
reduction in signaling potency (more than 10-fold) but not in a significantly reduced maximal 
response, suggesting that the sequences mutated play more a role in the coupling to Gq/11 but not 
in its activation. The notion of impaired coupling of the ICL-2 mutants is also supported by the 
fact that despite the high expression levels of mutants 2/3 – 2/5 they could not be activated by 
B9430 or icatibant as observed for the highly expressing B2wt. In addition, they also displayed 
the lowest basal activities of all constructs, hinting at an inverse agonistic effect of these 
mutations with regard to the activation of Gq/11. 
In contrast, the cluster mutation 3/4 and a point mutation (T242) in ICL-3 resulted in semi-
active conformations, as they became clearly activated by the otherwise very poor partial 
agonists. Our observation that semi-active conformations do not necessarily result in increased 
basal activity has also been reported for bovine rhodopsin, where the mutation of tyrosine in the 
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highly conserved NPXXY-sequence to alanine did not result in increased basal activity, but 
turned a poor agonist into a potent one (Fritze et al., 2003). 
 
Concerning the affinities of the mutants at 37°C and at 4°C only three constructs (1/1, 2/3, and 
3/3) showed binding characteristics comparable to those observed for B2Rwt. All other mutants 
differed significantly at either 4°C or 37 °C, demonstrating that mutations in ICLs also affect the 
conformation of the extracellular binding site. Whether these different Kd values are inherent 
properties of the mutants due to a change of the overall receptor conformation, or reflect 
modified interactions with cytosolic proteins stabilizing certain receptor conformations, will 
require further study. 
 
Although a role of ICLs in receptor internalization has been reported for other family A 
GPCRs (Marion et al., 2006); (DeGraff et al., 2002) no significant differences were observed 
between the B2Rwts and the loop mutants regarding their internalization of [3H]BK. These results 
are consistent with our previous observation that the intracellular C-terminus is crucial for ligand-
induced receptor internalization (Faussner et al., 1998). We cannot exclude, however, that the 
effects of the mutations on interactions with either receptor kinases or arrestins were not strong 
enough to be detected under the conditions applied. It is also possible that the region pivotal for 
these interactions is the DRY sequence, which due to lack of surface binding of the triple mutant, 
could not be examined in this regard. Results with the CXCR5 receptor do, indeed, suggest 
binding of arrestins to the region of the DRY sequence (Huttenrauch et al., 2002). 
 
The sequence mutated in construct 3/5 (TERR) seems to be of high importance for expression as 
well as signaling. This mutant was poorly expressed and signaled poorly. This poor signaling was 
not necessarily due to the low expression, as demonstrated by mutants 1/2 and E66A, that 
exhibited similar low expression levels as 3/5 but did still signal well. Mutant 2/1 (DRY-
sequence) displayed no surface binding activity at all. This is most probably due to lack of 
glycosylation or phosphorylation or a combination of both. Both cluster mutants that exhibited 
the most extreme features, constructs 2/1 and 3/5, are the ones that contain the two highly 
conserved amino acids to be assumed to form the “ionic lock”, R3.50 and E6.30. Therefore, two 
point mutants were generated by substituting each amino acid by an alanine. 
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F.3 R3.50 in the DRY motif and E6.30 in the TERR motif as key players for 
the activation and trafficking of the human bradykinin B2 receptor 
 
An aim of this study was to determine the structural and functional role of the conserved basic 
residue R3.50 at the cytosolic end of TM3 and of the acidic residue E6.30 at the end of TM6 for 
the B2R. In addition, the hypothesis that they may form an ionic lock maintaining the inactive 
state of the receptor was tested. The latter would distinguish the B2R from other peptide GPCRs 
as most of them carry a positively charged residue in position 6.30. To this purpose, both charged 
residues were mutated to alanine and the constructs, R3.50A and E3.50A, were stably expressed 
in HEK 293 cells.  
 
F.3.1 Mutation of the arginine in the conserved DRY motif resulted in complete loss of G 
protein activation  
The location of the DRY motif at the cytosolic surface of GPCRs led to the suggestion that it 
might interact directly with the G protein (Wess, 1998). As we have seen, the triple mutation of 
the DRY motif to alanine resulted in a construct that was binding deficient (see construct 2/1). 
Substitution of R3.50 alone with an alanine completely abolished the ability to induce IP 
accumulation or the release of arachidonic acid upon agonist stimulation, thus pointing to the 
crucial importance of this residue for a productive interaction with G proteins. The crystal 
structure of bovine rhodopsin in its G protein interacting form demonstrates that the conserved 
arginine directly interacts with a backbone carbonyl group of the C-terminal G protein alpha 
helix (Scheerer et al., 2008). Our results strongly suggest a similar role for R3.50 in the B2R. In 
many GPCRs, exchange of R3.50 leads to a strong reduction in their ability to activate their 
cognate G proteins. The extent of this impairment, however, depends on the receptor under 
investigation and the amino acid used for replacement, the effect changes from total abolishment 
of G protein signaling as observed for the B2R to only minor reductions. (Acharya and Karnik, 
1996); (Scheer et al., 1996); (Ballesteros et al., 1998); (Wess, 1998) (Rovati et al., 2007). In part 
the effect may depend on the assay: for the angiotensin receptor AT1a, mutation of R3.50 to alanine 
resulted in complete loss of G protein activation when measured as release of inositoltrisphosphate  
(IP3) after 10 seconds (Ohyama et al., 2002), but did not significantly affect the signaling compared 
to wild-type AT1a when accumulation of IP2 and IP3 was determined over a stimulation period of 20 
min (Gaborik et al., 2003). It is therefore, difficult to compare the effects of R3.50 mutations among 
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different GPCRs, but the array of published data indicates that the structural/functional role of 
R3.50 in family A GPCRs depends strongly on its particular microenvironment in the GPCR under 
investigation.  
R3.50A showed an increased binding affinity at 37°C compared to the B2 wild type receptor. 
The observed enhanced binding affinity for agonist ligands concerning some R3.50 mutant 
receptors has also been reported earlier (Scheer et al., 1996); (Scheer et al., 2000); (Alewijnse et 
al., 2000). According to the extended ternary complex model of GPCR activation (Samama et al., 
1993), mutant receptors with enhanced agonist affinity are stabilized in an activated conformation 
and able to bind G proteins, even though G protein signaling is disrupted.  
 Desensitization of many family A GPCRs is initiated by phosphorylation of 
serine/threonine residues located in the C-terminus via the action of GPCR kinases (GRK), 
mostly GRK2 and 3, resulting in recruitment of arrestins to the receptor and subsequent 
internalization. A proposed model for this mechanism is that GRK2 and GRK3 bind to the 
membrane close to the active receptor by attaching with their pleckstrin homology domains to βγ-
subunits that are available only after activation of the G-protein and dissociation of the α-subunit 
(Willets et al., 2003). However, mutant R3.50A displaying increased basal phosphorylation (Fig. 
E-31) responds to BK challenge with additional phosphorylation and strong internalization, 
although it is G-protein-activation incompetent (Fig. E-25). A different mechanism or other 
GRKs or kinases may therefore be involved in its phosphorylation and internalization. 
 
F.3.2 Mutation of E6.30 to alanine resulted in a similar phenotype as R3.50A but with 
quantitatively stronger effects 
The present study suggests that residues R3.50 and E6.30 form an ionic lock in the B2R as 
mutation of these two residues resulted in a similar receptor phenotype with regard to 
permanently increased receptor affinity (Fig. E-24, Tab. 4) and strong ERK1/2 phosphorylation 
(Fig. E-32) in response to poor partial agonists. This idea was strongly substantiated further by 
the fact that both mutants displayed the same constitutively activated phenotype with regard to 
receptor internalization, as demonstrated by, (i) the results of the biotinylation protection assay 
(Fig. E-27), (ii) their internalization of [3H]BK and uptake of antagonist [3H]NPC17331 (Fig. E-
26), as well as (iii) their substantial intracellular localization in the absence of an agonist (Fig. E-
28).  
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In addition, these data clearly demonstrate that ERK1/2 phosphorylation and ligand-induced 
receptor internalization can also function independently of G-protein-coupling, as both processes 
were observed not only for mutant E6.30A but also for G-protein activation incompetent mutant 
R3.50A (Fig. E-32 and Fig. E-26). Together with the fact that mutant R3.50A internalized after 
agonist-binding, i.e. most likely interacts with β-arrestins, this suggests that phosphorylation of 
ERK1/2 is β-arrestin mediated, as shown for the angiotensin II receptor AT1A (Ahn et al., 2004) 
Mutation of E6.30 in B2R resulted qualitatively in a similar phenotype as mutation of R3.50 to 
alanine but quantitatively always imposed the stronger effects (Table 5). 
 
Table 5. Summary of results: 
 B2Rwt R3.50A E6.30A 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
surface receptor binding +++ + + 
high affinity at 37°C - ++ +++ 
[3H]BK internalization +++ +++ +++ 
[3H]NPC17331 uptake - + ++ 
Gq/11 activation (BK) +++ - +++ 
Gq/11 activation (B9430/icatibant) - - +++ 
intracellular localization - + ++ 
constitutive internalization - + ++ 
(biotinylation protection assay) 
(-) no effect, (+) weak, (++) moderate, (+++) strong effect 
 
This could be explained by assuming that residue E6.30 has an additional interaction partner that 
can partially compensate the loss of the interaction with R3.50. Arginine R3.50 is also most 
likely involved in interaction with other than glutamate E6.30 in helix 6. The crystal structure of 
dark state bovine rhodopsin (PDB 1U19) indicates that R3.50 also makes contact with threonine 
T6.26(251), one turn above E6.30 in helix 6 (Scheerer et al., 2008). This residue is conserved in 
B2R and we have published that substitution of T6.26 by an alanine results in a semi-active 
mutant, as demonstrated by its higher affinity at 37°C and its antagonist-inducible IP 
accumulation (Faussner et al., 2009). 
Depending on how mutations in the E/DRY sequence affected receptor properties, Rovati et al. 
proposed a classification for family A GPCRs (Rovati et al., 2007). The B2R, however, does not 
fit well in either of the suggested groups: mutation R3.50A resulted in complete loss of G protein 
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activation, which would place it preferably in the second group, whereas the fact that R3.50A 
displays increased affinity for BK and responds to (ant)agonist stimulation with receptor 
internalization and ERK1/2 phosphorylation would rather qualify it for the first group. Further 
characterization of family A GPCRs not only according to the effects of mutations in the DRY 
sequence with regard to their G protein activation behavior but also considering effects on other 
signaling pathways might facilitate the classification.  
 
In summary, the results of our study demonstrate that R3.50 at the cytosolic end of TM3 in the 
human B2R plays a dual role: it is (i) pivotal for the productive interaction with G-proteins and 
(ii) is part of a network connecting TM3 and TM6 through a salt bridge with E6.30 and a 
hydrogen bond with T2426.26 maintaining the receptor in its inactive state. Disruption of these 
interactions results in a semi-active, easier activatable receptor state with regard to G-protein 
activation and the MAPkinase pathway, and in a constitutively active state with regard to the 
internalization machinery. Residue E6.30 might have an additional interaction partner as its 
mutation resulted in higher constitutive activity than mutation of R3.50. As an acidic residue in 
position 6.30 is only poorly conserved among the peptide receptors of family A GPCRs and often 
is replaced by a positively charged arginine or lysine, different mechanisms for maintaining their 
inactive state in the absence of an agonist must exist. 
 
F.3.3 Three-dimensional model of the bradykinin B2 receptor 
A three-dimensional model of the bradykinin B2 receptor based on the crystal structure of 
inactive bovine rhodopsin as seen from the cytosol was generated by homology modeling (Fig. F-
2). It indicates that sequences where mutations result in semi-active/constitutively active 
conformations are all part of a network and are clearly separated from those related to potency 
reduction. The latter ones, sequences mutated in constructs 2/4 and 2/5, apparently contribute to 
the binding but not to the activation of G protein Gq/11 by the receptor. Thus, this model provides 
a link between our screening study of the intracellular loops and the more detailed study of R3.50 
(R128) and E6.30 (E238). Finally, this model suggests K142 as an additional interaction partner 
for E6.30 (E238), that might help to compensate to some degree a loss of R3.50, which would 
explain the fact that mutant R3.50A displayed weaker semi- and constitutive activity than mutant 
E6.30A. 
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Fig. F-1: Position of mutations and their effects in a three-dimensional model of the bradykinin B2 receptor 
based on the crystal structure of inactive bovine rhodopsin as seen from the cytosol. 
Position of mutants and annotation of their effects in a computational model of B2R as seen from the cytosol. 
The structure was generated with SWISS-model (Arnold et al.) based on the crystal structure of bovine 
rhodopsin in its inactive form (PDB 1U19A [Okada et al.]). Dark blue, cytosolic ends of the seven 
transmembrane helices I – VII and cytosolic helix VIII; point and cluster mutants are depicted in black and 
white as in Fig. E-15 (only alpha-carbon chain shown, no side chains, with the exception of R3.50 [R128] in 
blue, E6.30 [E238] in red, and T6.26[T242] in yellow, and K142 in blue; grey, amino acids not mutated 
outside of the helices; green squares, effect of indicated mutations on receptor properties. Mutant names 
depicted in black oval indicate semi-/constitutively active conformations. 
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G SUMMARY 
The aim of the presented thesis was to study the regulation of the human bradykinin B2 receptor 
(B2R) with regard to signal transduction pathways, receptor desensitization, and receptor 
internalization. 
 
In the first part the influence of human bradykinin B2 receptor densities and cell types on receptor 
internalization and signal transduction was investigated. The properties of the B2R stably 
expressed at two considerably different expression levels by using two different promoters in 
HEK 293 cells, and the endogenously expressed B2R in human fibroblasts were analyzed. It was 
demonstrated that two B2R antagonists, icatibant and B9430 that differ from BK through the 
insertion of unnatural amino acids, under certain conditions become partial agonists. This partial 
agonism was only obtained in HEK 293 cells expressing high amounts of recombinant B2R. In 
contrast, in lower (HEK 293) or endogenously (foreskin fibroblasts) expressing cells, no partial 
agonism of these two compounds was observed. However, in low expressing HEK293 cells as 
well as in the fibroblasts long-term challenge with B9430, but not icatibant, strongly reduced 
receptor surface binding, comparable to the effect seen for the endogenous agonist BK. Further 
studies revealed that in contrast to BK, which reduced surface binding through induction of 
receptor internalization, B9430 reduced binding apparently via a change in the affinity of the 
B2R on the cell surface without promoting its internalization.  
 
In the second part of this thesis the role of the intracellular loops of the human bradykinin B2 
receptor was explored in detail. G proteins, receptor kinases and adaptor proteins of the 
internalization machinery most likely interact with the cytosolic parts of the receptor. In order to 
more closely define the receptor sequences that are involved in these interactions, we 
systematically mutated all three intracellular loops either as point mutants or in groups of 3-5 
amino acids to alanines (obtaining 14 mutants). All constructs were stably and isogenically 
expressed in HEK 293 cells. Our results show that changes in the intracellular loop 1 (ICL-1) 
strongly affect receptor surface expression but not receptor signaling or receptor internalization. 
Even more important for receptor maintenance are the DRY-sequence at the N-terminus of 
intracellular loop 2 (ICL-2) and the TERR-sequence at the C-terminus of intracellular loop 3 
(ICL-3), as cluster mutations here completely abolish or strongly reduce surface receptor 
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expression, respectively. Both ICL-2 and ICL-3 are involved in the interaction with G protein 
Gq/11 but in different ways. Sequences in ICL-2 contribute apparently more to the coupling, 
regions in ICL-3 preferentially to the activation of Gq/11.  
 
As a consequence of the results of the second part, a closer look was taken at the role of single 
amino acids in the DRY- and the TERR sequence. For bovine rhodopsin it has been shown that 
the arginine in the DRY motif (R3.50 according to the Ballesteros/Weinstein numbering) 
(Ballesteros et al., 1998) and a glutamate at the cytosolic end of transmembrane domain 6 
(Ballesteros/Weinstein position 6.30) corresponding to the glutamate in the TERR sequence of 
the B2R, form an intramolecular interaction keeping rhodopsins in its inactive state. This 
interaction in bovine rhodopsin is also known as the “ionic lock” and is assumed to be disrupted 
as part of receptor activation. The B2R is one of the very few peptide GPCRs where both R3.50 
and a glutamic acid in position 6.30 can be found. Therefore, in the third part of the thesis the 
structural and functional role of the conserved basic residue R3.50 and the acidic residue E6.30 in 
the human B2R were investigated. In addition, the hypothesis was tested that they may form an 
“ionic lock“ participating in maintaining the inactive state of the B2R. This goal was pursued by 
generation of two receptor point mutants, termed R3.50A and E6.30A, and their extensive 
biochemical and functional characterization. 
The results of this study demonstrate that R3.50 plays a dual role: it is (i) pivotal for the 
productive interaction with G-proteins and (ii) is most likely part of a network where it connects 
TM3 and TM6 through a salt bridge with E6.30 and a hydrogen bond with T6.26 maintaining the 
receptor in its inactive state. The second point is indicated by the fact, that - with exception the of 
G-protein activation - both mutants R3.50A and E6.30 displayed an almost identical pattern of 
constitutive and semi-active activity, as expected when both residues interact with each other. 
Residue E6.30 might have an additional interaction partner as its mutation resulted in stronger 
active conformations than mutation of R3.50. As an acidic residue in position 6.30 is not well 
conserved among the peptide receptor of family A GPCRs and often is replaced by a positively 
charged arginine or lysine, different regulation mechanisms must exist in this GPCR subfamily. 
 
GPCRs are an ideal therapeutic target as they are on the one hand well accessible on the cell 
surface on the other hand act very specifically by binding their endogenous ligands with high 
selectivity and display cell specific expression patterns. Deeper insight into structure, differences 
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and similarities of their regulation should allow a more rational, structure-based development of 
drugs and thus make better use of their full therapeutic potential. 
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